var title_f42_60_43968="Ligation uterine vsls 1";
var content_f42_60_43968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ligation of uterine vessels during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43968=[""].join("\n");
var outline_f42_60_43968=null;
var title_f42_60_43969="Patient information: Smoking in pregnancy (The Basics)";
var content_f42_60_43969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85813\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/20/27970\">",
"         Patient information: Preterm labor (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Smoking in pregnancy (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H118310020\">",
"      <span class=\"h1\">",
"       How can smoking affect my pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who smoke during pregnancy are more likely than those who do not smoke to have serious problems during pregnancy. These problems include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Preterm labor - This is labor that starts before 37 weeks of pregnancy (3 or more weeks before the woman&rsquo;s due date). Pregnancy normally lasts about 40 weeks, counting from the first day of the woman&rsquo;s last period. Going into labor before 37 weeks of pregnancy can be dangerous, because babies who are born preterm (also called &ldquo;premature&rdquo;) can have serious health problems.",
"       </li>",
"       <li>",
"        Problems with the placenta (",
"        <a class=\"graphic graphic_figure graphicRef82935 \" href=\"mobipreview.htm?7/20/7495\">",
"         figure 1",
"        </a>",
"        ) &ndash; These can include &ldquo;placenta previa&rdquo; and &ldquo;placental abruption.&rdquo; Placenta previa happens when the placenta covers the opening of the cervix. Placental abruption happens when the placenta separates from the mother&rsquo;s uterus before the baby is born. Both of these problems can cause bleeding from the vagina.",
"       </li>",
"       <li>",
"        Miscarriage &ndash; A miscarriage is when a pregnancy ends before a woman has been pregnant for 20 weeks.",
"       </li>",
"       <li>",
"        Stillbirth &ndash; A stillbirth is when a baby dies before it is born, in the second half of pregnancy (after 20 weeks).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H118310035\">",
"      <span class=\"h1\">",
"       How can smoking during pregnancy affect my baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies whose mothers smoke during pregnancy are more likely than babies whose mothers do not smoke to: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Be premature or be born too small &ndash; Babies who are premature or small are more likely to have problems with feeding, sleeping, breathing, seeing, and hearing.",
"       </li>",
"       <li>",
"        Die suddenly for no known reason before the age of 1 year (this is called &ldquo;sudden infant death syndrome&rdquo; or &ldquo;SIDS&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      What treatments can help me stop smoking during pregnancy?",
"     </p>",
"     <p>",
"      Your doctor or nurse can give you advice on the best way to quit. He or she can also put you in touch with counselors or other people you can call for support. The letters in the word &ldquo;START&rdquo; can help you remember the steps to take:",
"     </p>",
"     <p>",
"      S = Set a quit date.",
"     </p>",
"     <p>",
"      T = Tell family, friends, and the people around you that you plan to quit.",
"     </p>",
"     <p>",
"      A = Anticipate or plan ahead for the tough times you'll face while quitting.",
"     </p>",
"     <p>",
"      R = Remove cigarettes and other tobacco products from your home, car, and work.",
"     </p>",
"     <p>",
"      T = Talk to your doctor about getting help to quit.",
"     </p>",
"     <p>",
"      The earlier you can quit smoking in your pregnancy, the better. But stopping at any point can still help. If you cannot quit, smoking fewer cigarettes can help, too.",
"     </p>",
"     <p>",
"      It&rsquo;s also very important not to start smoking again after your baby is born. Babies who are around smoke from cigarettes (called &ldquo;second-hand smoke&rdquo;) have a higher-than-normal risk of health problems, such as colds and ear infections. Quitting for good also lowers your chances of heart disease and cancer. And it sets a good example for your child not to smoke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H118310050\">",
"      <span class=\"h1\">",
"       Can I take medicines to help me quit smoking while I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have tried other ways to quit smoking but still can&rsquo;t stop, you can try medicines. Ask your doctor which would be safest for you and your baby. Medicines to help you quit include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Nicotine replacement therapy &ndash; This includes skin patches, lozenges, and gum that have nicotine. Prescription forms include nasal sprays and &ldquo;puffers&rdquo; (also called &ldquo;inhalers&rdquo;).",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/7/17526?source=see_link\">",
"         Bupropion",
"        </a>",
"        &ndash; This prescription medicine reduces your desire to smoke. This medicine is sold under the brand names Zyban&reg; and Wellbutrin&reg;. It is also available in a generic version, which is cheaper than the brand name ones. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H118310067\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/20/27970?source=see_link\">",
"       Patient information: Preterm labor (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/60/43969?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85813 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-0E38AEEEDF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43969=[""].join("\n");
var outline_f42_60_43969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118310020\">",
"      How can smoking affect my pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118310035\">",
"      How can smoking during pregnancy affect my baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118310050\">",
"      Can I take medicines to help me quit smoking while I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118310067\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85813\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43970="Patient information: Dyspareunia (painful sex) (The Basics)";
var content_f42_60_43970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83160\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/2/12322\">",
"         Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/11/20658\">",
"         Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/23/42353\">",
"         Patient information: Chronic pelvic pain in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/11/29873\">",
"         Patient information: Prostatitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/33/36370\">",
"         Patient information: Vulvar pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/48/31490\">",
"         Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/22/17764\">",
"         Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/23/7537\">",
"         Patient information: Vaginal dryness (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dyspareunia (painful sex) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dyspareunia-painful-sex-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H17215599\">",
"      <span class=\"h1\">",
"       What is dyspareunia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dyspareunia is pain that happens just before, during, or after sex. It can happen in men and women, but is more common in women.",
"     </p>",
"     <p>",
"      Women can have pain at the vulva, the area around the opening of the vagina. Or the pain can be inside the vagina or in the lower belly (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). Men can have pain in the penis, testicles, belly, and sometimes the rectum.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17215614\">",
"      <span class=\"h1\">",
"       What causes dyspareunia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many possible causes.",
"     </p>",
"     <p>",
"      In women, common causes include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Childbirth &ndash; Sex can be painful for several weeks or months after giving birth. &nbsp;",
"       </li>",
"       <li>",
"        Endometriosis &ndash; In this condition, tissue that normally grows inside a woman&rsquo;s uterus grows outside it. This can cause pain in the belly during sex.",
"       </li>",
"       <li>",
"        Vaginal dryness &ndash; This can be caused by:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Menopause &ndash; This is the time in a woman&rsquo;s life when she stops having periods. The vagina and tissues around it can get dry and thin at menopause. This can make sex hurt. &nbsp;",
"       </li>",
"       <li>",
"        Not being aroused or &ldquo;excited&rdquo; before sex",
"       </li>",
"       <li>",
"        An infection in the vagina or bladder",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Conditions that cause long lasting pain in the vulva, bladder, or pelvis &ndash; These can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A condition called &ldquo;vulvodynia&rdquo; &ndash; This is pain in the vulva.",
"       </li>",
"       <li>",
"        A condition called &ldquo;interstitial cystitis&rdquo; &ndash; This condition causes bladder pain and other symptoms.",
"       </li>",
"       <li>",
"        A condition called &ldquo;chronic pelvic pain&rdquo; &ndash; This is pain in the area below the belly button that lasts 6 months or longer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Skin problems around the vagina",
"       </li>",
"       <li>",
"        Bad feelings about a partner or relationship &ndash; Feeling bad about your partner or about yourself can make sex hurt.",
"       </li>",
"       <li>",
"        A painful experience in the past &ndash; This could be a past experience of sex or a medical exam that hurt. It could even be pain from using a tampon.",
"       </li>",
"       <li>",
"        Birth control pills &ndash; Some women who take birth control pills start having pain during sex.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In men, common causes include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Infections &ndash; These can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        An infection in the prostate &ndash; The prostate is a gland that makes some of the fluid men release during sex. Infections in other parts of the body can also make sex hurt.",
"       </li>",
"       <li>",
"        Infection with a disease spread through sex, such as gonorrhea.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Skin problems",
"       </li>",
"       <li>",
"        Bad feelings about a partner or relationship &ndash; Feeling bad about a partner or about yourself can make sex painful.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17215629\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If sex is painful, see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17215646\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, other symptoms, and individual situation. He or she will do an exam and ask you about your symptoms.",
"     </p>",
"     <p>",
"      Here are some common tests doctors use to find the cause of dyspareunia:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Urine tests &ndash; These can look for a bladder infection.",
"       </li>",
"       <li>",
"        If you are a woman, tests on a sample of fluid from your vagina - These can look for an infection in the vagina.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17215663\">",
"      <span class=\"h1\">",
"       How is dyspareunia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments for women include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics or antifungal medicines &ndash; These can help if the pain is caused by an infection in the vagina or bladder.",
"       </li>",
"       <li>",
"        Using creams or gels to keep the vagina moist, or a prescription cream to treat vaginal dryness (usually estrogen) or a skin condition.",
"       </li>",
"       <li>",
"        Using a numbing gel or ointment before and after sex.",
"       </li>",
"       <li>",
"        Physical therapy to loosen the muscles around the vagina.",
"       </li>",
"       <li>",
"        Counseling &ndash; If pain is caused by bad feelings about sex, a relationship, or yourself.",
"       </li>",
"       <li>",
"        Surgery &ndash; A few women have pain that is caused by a growth inside the body. Doctors might do surgery to take out the growth.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatments for men include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to treat infection or other conditions that cause pain &ndash; These can include antibiotics and other medicines. &nbsp;",
"       </li>",
"       <li>",
"        Treatment for skin problems",
"       </li>",
"       <li>",
"        Counseling &ndash; If pain could be caused by feeling bad about sex, a relationship, or yourself. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17215584\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/11/29873?source=see_link\">",
"       Patient information: Prostatitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/11/20658?source=see_link\">",
"       Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/23/42353?source=see_link\">",
"       Patient information: Chronic pelvic pain in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/2/12322?source=see_link\">",
"       Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/33/36370?source=see_link\">",
"       Patient information: Vulvar pain (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"       Patient information: Vaginal dryness (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/22/17764?source=see_link\">",
"       Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=see_link\">",
"       Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/60/43970?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83160 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43970=[""].join("\n");
var outline_f42_60_43970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17215599\">",
"      What is dyspareunia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17215614\">",
"      What causes dyspareunia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17215629\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17215646\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17215663\">",
"      How is dyspareunia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17215584\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/2/12322?source=related_link\">",
"      Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/11/20658?source=related_link\">",
"      Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/23/42353?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=related_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/11/29873?source=related_link\">",
"      Patient information: Prostatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/22/17764?source=related_link\">",
"      Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/33/36370?source=related_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43971="Chloroprocaine: Patient drug information";
var content_f42_60_43971=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chloroprocaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/17/3350?source=see_link\">",
"     see \"Chloroprocaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/31/9716?source=see_link\">",
"     see \"Chloroprocaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nesacaine&reg;;",
"     </li>",
"     <li>",
"      Nesacaine&reg;-MPF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nesacaine&reg;-CE",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chloroprocaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is given on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11932 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-103.10.120.51-2DFBF20D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43971=[""].join("\n");
var outline_f42_60_43971=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016605\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016604\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016609\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016610\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016612\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016607\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016608\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016613\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016614\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/17/3350?source=related_link\">",
"      Chloroprocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/31/9716?source=related_link\">",
"      Chloroprocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43972="Sweet syndrome";
var content_f42_60_43972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous annular plaque lesions on the neck of a patient (left panel). Vesicular and pustular lesions of Sweet syndrome involving the buttocks (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43972=[""].join("\n");
var outline_f42_60_43972=null;
var title_f42_60_43973="Triamterene: Drug information";
var content_f42_60_43973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamterene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/33/42516?source=see_link\">",
"    see \"Triamterene: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/1/1045?source=see_link\">",
"    see \"Triamterene: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dyrenium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Potassium Sparing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Edema, hypertension:",
"     </b>",
"     Oral: 100-300 mg/day in 1-2 divided doses; maximum dose: 300 mg/day; usual dosage range (JNC 7): 50-100 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4473152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/1/1045?source=see_link\">",
"      see \"Triamterene: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Oral: Initial: 1-2 mg/kg/day in 2 divided doses; maximum: 3-4 mg/kg/day, up to 300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F230704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F230705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose reduction is recommended in patients with cirrhosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dyrenium&reg;: 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9626944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alone or in combination with other diuretics in treatment of edema and hypertension; decreases potassium excretion caused by kaliuretic diuretics",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Triamterene may be confused with trimipramine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dyrenium&reg; may be confused with Pyridium&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, CHF, edema, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Dehydration, gynecomastia, impotence, metabolic acidosis, postmenopausal bleeding",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triamterene or any component of the formulation; patients receiving other potassium-sparing diuretics; anuria; severe hepatic disease; hyperkalemia or history of hyperkalemia; severe or progressive renal disease; pregnancy (expert analysis)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte loss: Excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia:",
"     <b>",
"      [U.S. Boxed Warning]: Hyperkalemia can occur; patients at risk include those with renal impairment, diabetes, the elderly, and the severely ill. Serum potassium levels must be monitored at frequent intervals especially when dosages are changed or with any illness that may cause renal dysfunction.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Can cause photosensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kidney stones: Use with caution in patients with kidney stones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium supplements: Avoid potassium supplements, potassium-containing salt substitutes, a diet rich in potassium, or other drugs that can cause hyperkalemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Triamterene may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indomethacin: May enhance the nephrotoxic effect of Triamterene. Management: Consider alternatives to concomitant treatment with triamterene and indomethacin.  If the combination cannot be avoided, monitor for development of renal failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available. Generally, use of diuretics during pregnancy is avoided due to risk of decreased placental perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F230691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F230692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F230689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Dyrenium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $168.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $282.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F230680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum electrolytes (especially potassium), renal function; weight, I &amp; O",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diurene (ES);",
"     </li>",
"     <li>",
"      Dyrenium (CH);",
"     </li>",
"     <li>",
"      Dytac (BE, BF, BJ, CI, ET, GB, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Jatropur (DE);",
"     </li>",
"     <li>",
"      Maxzide (TW);",
"     </li>",
"     <li>",
"      Triamteren (HU, PL);",
"     </li>",
"     <li>",
"      Triamthiazid (DE);",
"     </li>",
"     <li>",
"      Uretren (FI);",
"     </li>",
"     <li>",
"      Urocaudal (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks epithelial sodium channels in the late distal convoluted tubule (DCT) and collecting duct which inhibits sodium reabsorption from the lumen. This effectively reduces intracellular sodium, decreasing the function of Na+/K+ ATPase, leading to potassium retention and decreased calcium, magnesium, and hydrogen excretion. As sodium uptake capacity in the DCT/collecting duct is limited, the natriuretic, diuretic, and antihypertensive effects are generally considered weak.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 7-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Unreliable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43973/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43973/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43973/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43973/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10016 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43973=[""].join("\n");
var outline_f42_60_43973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708892\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230722\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230702\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4473152\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230703\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230704\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230705\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230666\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9626944\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230683\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230730\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230720\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230687\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230670\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300169\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230675\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230677\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230706\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230691\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230692\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230689\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230680\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038850\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230669\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230686\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10016\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10016|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/33/42516?source=related_link\">",
"      Triamterene: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/1/1045?source=related_link\">",
"      Triamterene: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43974="Management of ibuprofen poisoning in children and adolescents";
var content_f42_60_43974=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of ibuprofen poisoning in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43974/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43974/contributors\">",
"     Rebecca T Kirkland, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43974/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43974/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43974/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43974/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/60/43974/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    is a nonsteroidal antiinflammatory drug (NSAID) that is available over-the-counter and is commonly ingested by children and adolescents. After oral ingestion, most patients are asymptomatic and few require supportive care or hospitalization. However, patients who ingest more than 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of ibuprofen are at risk for serious toxicity, including apnea, bradycardia, hypotension, severe metabolic acidosis, polyuria with renal failure, coma, and seizures.",
"   </p>",
"   <p>",
"    The evaluation and management of acute overdose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    in children and adolescents is reviewed here. The management of acute overdose of nonsteroid antiinflammatory drugs, including ibuprofen, in adults and the chronic toxicity of NSAIDs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/47?source=see_link\">",
"     \"Nonsteroidal antiinflammatory drug (NSAID) poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13384251\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    is a nonsteroidal antiinflammatory drug (NSAID) that has been available as an over-the-counter preparation since 1984 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/1\">",
"     1",
"    </a>",
"    ]. In the nine years prior to 1984, 100 million prescriptions for ibuprofen were written in the United States with only 67 cases of overdose or accidental ingestions reported, 25 of which occurred in children younger than three years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/2\">",
"     2",
"    </a>",
"    ]. According to the American Association of Poison Control Centers&rsquo; National Data System, since being available over-the-counter, ibuprofen accounts for almost 70,000 exposures in children and adolescents annually with the majority of reports occurring in children under six years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/47?source=see_link\">",
"     \"Nonsteroidal antiinflammatory drug (NSAID) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    is a propionic acid derivative. Like other NSAIDs, it inhibits cyclooxygenase (prostaglandin synthase), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"mobipreview.htm?33/29/34269\">",
"     figure 1",
"    </a>",
"    ). Ibuprofen has analgesic, antipyretic, antiinflammatory, and uterine muscle effects that largely are caused by reduced prostaglandin synthesis although other mechanisms of action are proposed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2426996\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    are as follows (see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     \"Ibuprofen: Drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/47?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonsteroidal antiinflammatory drug (NSAID) poisoning\", section on 'Kinetics'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absorption is 85 percent after oral ingestion.",
"     </li>",
"     <li>",
"      Peak effect occurs one to two hours following normal doses. The effect may be delayed up to four hours after toxic ingestions.",
"     </li>",
"     <li>",
"      Volume of distribution is 0.1 to 0.2",
"      <span class=\"nowrap\">",
"       L/kg",
"      </span>",
"      with high protein binding (90 to 99 percent).",
"     </li>",
"     <li>",
"      Half-life of elimination in children is two hours after a regular dose, but may be prolonged in overdose.",
"     </li>",
"     <li>",
"      Metabolism occurs completely in the liver and inactive metabolites are excreted by the kidney.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience based upon millions of doses given reveals no problems specific to children that would limit the usefulness of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    in children six months of age or older. However, safety and efficacy have not been established for younger children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among children 6 months to 12 years of age, the regular oral dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    varies with the indication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For antipyretic effect, the typical dose is 10",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      the dose is given every six to eight hours. The maximum daily dose is 40",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=see_link&amp;anchor=H70205006#H70205006\">",
"       \"Pathophysiology and management of fever in infants and children\", section on 'Ibuprofen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For antiinflammatory activity, the initial dose is 30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) in three or four divided doses. Some children with mild disease may respond to as little as 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    therapy encompass adverse effects and allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2427159\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children taking prescription doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (eg, for rheumatic diseases), 10 to 30 percent develop gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. When ibuprofen is used for analgesia or antipyretic effect at lower doses, adverse effects, including gastrointestinal symptoms, asthma exacerbation or renal adverse effects, occur in approximately 14 percent of patients, which is not significantly different from adverse effects after",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, intermittent oral dosing of ibuprofen is equally or more efficacious for the management of fever and pain than acetaminophen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Suggested approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combined antipyretic therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    alternating with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may increase the risk for renal toxicity, especially in children with dehydration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=see_link&amp;anchor=H70205060#H70205060\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Combining or alternating therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2427216\">",
"    <span class=\"h3\">",
"     Patients at increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    should be given with caution to children at high risk for side effects, including those with a history of effective volume depletion (including heart failure), gastrointestinal disease, hepatic or renal disease, systemic lupus erythematosus (particularly if associated with renal involvement), or a bleeding diathesis (including anticoagulant therapy), each of which can be worsened by NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In high-risk patients, ibuprofen can produce a variety of adverse effects, such as acute renal failure, worsening heart failure, and decreased responsiveness to diuretics and antihypertensive drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    should not be routinely used for fever control in infants under six months of age because of potential renal toxicity caused by their limited renal function relative to older infants and children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=see_link&amp;anchor=H70205006#H70205006\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Ibuprofen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2427173\">",
"    <span class=\"h2\">",
"     Allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated allergic reactions can occur after therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or other NSAIDs. Symptoms in this setting include allergic rhinitis, rash, and urticaria. In addition, patients with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    exacerbated respiratory disease should avoid all nonsteroidal antiinflammatory drugs, including ibuprofen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link&amp;anchor=H22#H22\">",
"     \"Aspirin exacerbated respiratory disease\", section on 'NSAID avoidance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF ACUTE OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important historical information includes the amount of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ingested, the time of ingestion, and the presence of coingestants. Caregivers should be specifically questioned about their use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    , as these are commonly mistaken for ibuprofen and can produce significant toxicity.",
"   </p>",
"   <p>",
"    In most instances, the child will be asymptomatic and the physical examination will be unremarkable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. When symptoms do occur, they usually present within four hours of ingestion and include nausea, vomiting, headache, drowsiness, blurred vision, tinnitus, ataxia, and dizziness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Symptoms are unlikely at doses &le;100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Life-threatening toxicity is rare and usually occurs at ingested doses &gt;400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Features of life-threatening poisoning include apnea, bradycardia, hypotension, anion gap metabolic acidosis, polyuria with renal failure, coma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2427691\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who only ingest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and who have either mild symptoms that resolve or are asymptomatic do not need routine laboratory studies. Patients with significant toxicity should undergo the following evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid blood glucose if altered mental status is present",
"     </li>",
"     <li>",
"      Serum electrolytes, blood urea nitrogen (BUN), and creatinine",
"     </li>",
"     <li>",
"      Blood gas determination",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      level (if suicide attempt or if acetaminophen coingestion is suspected in an otherwise asymptomatic patient)",
"     </li>",
"     <li>",
"      Salicylate level, especially if an anion gap metabolic acidosis is present",
"     </li>",
"     <li>",
"      Complete blood count with platelets",
"     </li>",
"     <li>",
"      Urinary pregnancy test in postmenarchal females",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    levels are not rapidly available and do not correlate well with toxicity or outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, they are not useful for guiding acute management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pediatric",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    overdose is supportive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/11\">",
"     11",
"    </a>",
"    ]. No antidote exists to treat ibuprofen toxicity. Nomograms using serum drug concentrations do not appear to be predictive of toxicity and are not useful in the management of overdoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13384182\">",
"    <span class=\"h2\">",
"     Airway, breathing, circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any poisoned patient, the clinician's first responsibility is to secure the airway, breathing, and circulation (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"mobipreview.htm?17/26/17837\">",
"     table 1",
"    </a>",
"    ). Apnea and hypotension are rare, and aggressive intervention is usually unnecessary. If intubation and mechanical ventilation are necessary, it is important to adjust the ventilator appropriately to help compensate for any underlying acidosis. Patients with shock should receive fluid resuscitation, and if poor response, treatment with vasopressors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Extracorporeal membrane oxygenation was used successfully in one patient with hypotension refractory to fluid resuscitation and vasopressor administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43974/abstract/13\">",
"     13",
"    </a>",
"    ]. However such invasive measures are not recommended or necessary in most cases. We recommend consultation with a regional poison control center or medical toxicologist to determine if such therapeutic techniques are warranted, as may be the case in patients with severe metabolic acidosis or renal failure. (See",
"    <a class=\"local\" href=\"#H13384559\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13384189\">",
"    <span class=\"h2\">",
"     Other supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are the initial treatment for seizures caused by",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    poisoning with further management dictated by the child&rsquo;s response (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"mobipreview.htm?29/20/30029\">",
"     table 2",
"    </a>",
"    ). Metabolic acidosis that is severe and unresponsive to fluid administration may warrant",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13384196\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children who are alert and present for care within one hour of an",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    overdose receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC).&nbsp;Some clinicians may choose",
"    <strong>",
"     not",
"    </strong>",
"    to give AC to children who are asymptomatic, have coingestants reliably excluded, and whose ingested dose is &lt;100",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    The recommendation of AC administration following ibuprofen overdose derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    ) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H27#H27\">",
"     \"Decontamination of poisoned children\", section on 'Cathartics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H10032467#H10032467\">",
"     \"Decontamination of poisoned children\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link&amp;anchor=H18993761#H18993761\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link&amp;anchor=H18993978#H18993978\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Cathartics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H10032558#H10032558\">",
"     \"Decontamination of poisoned children\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link&amp;anchor=H26755739#H26755739\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Evidence of efficacy and adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    We recommend that children who ingest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    <strong>",
"     not",
"    </strong>",
"    undergo gastric emptying by gastric lavage or by syrup of ipecac induced emesis. This recommendation is based upon randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13384203\">",
"    <span class=\"h2\">",
"     Extracorporeal elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who ingest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    should not receive multiple doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC) because low enterohepatic circulation and high protein binding limits the effectiveness of this therapy. Because ibuprofen is highly protein bound hemodialysis is also ineffective despite ibuprofen&rsquo;s low volume of distribution (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     L/kg).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13384211\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ingestions &le;100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    who are asymptomatic and not suicidal may be safely discharged after a four to six hour period of observation. Such patients comprise the majority of children and adolescents who ingest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    . Children who become symptomatic after an ibuprofen overdose should be observed in the hospital to monitor for the development of neurologic symptoms or renal failure until symptoms subside.",
"    <br/>",
"    <br/>",
"    Suicidal patients, patients who manifest signs of severe intoxication (eg, pH &lt;7.3, acute renal dysfunction, altered mental status), and those with other medical or psychosocial concerns should be admitted. As with all poisonings, determination of coingestions (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    ) is important and will affect disposition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13114?source=see_link\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13384559\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20601393\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      is a nonsteroidal antiinflammatory drug (NSAID) that is commonly ingested by children and adolescents. (See",
"      <a class=\"local\" href=\"#H13384251\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2426996\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children who ingest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      are asymptomatic, especially if the ingested dose is &le;100",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features of acute overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When symptoms do occur, they usually present within four hours of ingestion and include nausea, vomiting, headache, drowsiness, blurred vision, tinnitus, ataxia, and dizziness. Life-threatening toxicity is rare and typically occurs at ingested doses over 400",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features of acute overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who only ingest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      and who have either mild symptoms that resolve or are asymptomatic do not need routine laboratory studies.",
"     </li>",
"     <li>",
"      Patients with significant toxicity should undergo further laboratory evaluation depending upon clinical circumstances. (See",
"      <a class=\"local\" href=\"#H2427691\">",
"       'Ancillary studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of pediatric",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      overdose is supportive. Aggressive intervention is rarely required. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13384182\">",
"       'Airway, breathing, circulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13384189\">",
"       'Other supportive measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children who are alert and present for care within one hour of an",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      overdose receive",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).&nbsp;Some clinicians may choose",
"      <strong>",
"       not",
"      </strong>",
"      to give AC to children who are asymptomatic, who have coingestants reliably excluded, and whose ingested dose is &le;100",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"     </li>",
"     <li>",
"      We recommend that children who ingest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      <strong>",
"       not",
"      </strong>",
"      undergo gastric emptying by gastric lavage or by syrup of ipecac induced emesis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Disposition following",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      overdose depends upon the clinical findings and circumstances surrounding the ingestion. Patients with ingested doses &le;100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      who are asymptomatic and not suicidal may be safely discharged after a four to six hour period of observation. (See",
"      <a class=\"local\" href=\"#H13384211\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/1\">",
"      Doyle G, Furey S, Berlin R, et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 1999; 13:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/2\">",
"      Barry WS, Meinzinger MM, Howse CR. Ibuprofen overdose and exposure in utero: results from a postmarketing voluntary reporting system. Am J Med 1984; 77:35.",
"     </a>",
"    </li>",
"    <li>",
"     Bronstein, AC, Spyker, DA, Cantilena, LR, et al. 2008 Annual Report of the American Association of Poison Control Centers&rsquo; National Poison Data System (NPDS): 26th Annual Report. Clinical Toxicology 2009; 47:911. file://aapcc.org/annual.htm.",
"    </li>",
"    <li>",
"     Drug Information for the Health Care Professional USPDI 19th Edition Micromedix 1999; p. 388.",
"    </li>",
"    <li>",
"     Dukes M. NG Meyler's Side Effects of Drugs: An Encyclopedia of Adverse Reactions and Interactions, 13th, Elsevier, Amsterdam 1996. p.228.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/6\">",
"      Flat&oslash; B, Vinje O, F&oslash;rre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin Rheumatol 1998; 17:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/7\">",
"      Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin 2009; 25:2207.",
"     </a>",
"    </li>",
"    <li>",
"     Ebadi M. CRC Desk Reference of Clinical Pharmacology, CRC Press, Boca Raton 1998. p.279.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/9\">",
"      Moghal NE, Hulton SA, Milford DV. Care in the use of ibuprofen as an antipyretic in children. Clin Nephrol 1998; 49:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/10\">",
"      Hall AH, Smolinske SC, Conrad FL, et al. Ibuprofen overdose: 126 cases. Ann Emerg Med 1986; 15:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/11\">",
"      Smolinske SC, Hall AH, Vandenberg SA, et al. Toxic effects of nonsteroidal anti-inflammatory drugs in overdose. An overview of recent evidence on clinical effects and dose-response relationships. Drug Saf 1990; 5:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/12\">",
"      Oker EE, Hermann L, Baum CR, et al. Serious toxicity in a young child due to ibuprofen. Acad Emerg Med 2000; 7:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/13\">",
"      Marciniak KE, Thomas IH, Brogan TV, et al. Massive ibuprofen overdose requiring extracorporeal membrane oxygenation for cardiovascular support. Pediatr Crit Care Med 2007; 8:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/14\">",
"      Levine M, Khurana A, Ruha AM. Polyuria, acidosis, and coma following massive ibuprofen ingestion. J Med Toxicol 2010; 6:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43974/abstract/15\">",
"      McElwee NE, Veltri JC, Bradford DC, Rollins DE. A prospective, population-based study of acute ibuprofen overdose: complications are rare and routine serum levels not warranted. Ann Emerg Med 1990; 19:657.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6503 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43974=[""].join("\n");
var outline_f42_60_43974=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20601393\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13384251\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2426996\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2427159\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2427216\">",
"      - Patients at increased risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2427173\">",
"      Allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES OF ACUTE OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2427691\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13384182\">",
"      Airway, breathing, circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13384189\">",
"      Other supportive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13384196\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13384203\">",
"      Extracorporeal elimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13384211\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13384559\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20601393\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6503|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/29/34269\" title=\"figure 1\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/26/17837\" title=\"table 1\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/20/30029\" title=\"table 2\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=related_link\">",
"      Ibuprofen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/47?source=related_link\">",
"      Nonsteroidal antiinflammatory drug (NSAID) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43975="Mannitol: Pediatric drug information";
var content_f42_60_43975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mannitol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"    see \"Mannitol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/34/29221?source=see_link\">",
"    see \"Mannitol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F12595457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aridol&trade;;",
"     </li>",
"     <li>",
"      Osmitrol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Osmitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Osmotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acute renal failure:",
"     </b>",
"     I.V.: 0.5-1 g/kg/dose (Andreoli, 2004); some experts recommend against routine use due to the risk of IVH in low birth weight neonates (solution is hypertonic) or the precipitation of CHF if a lack of response occurs (Andreoli, 2004; Chua, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"      see \"Mannitol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer&rsquo;s labeling recommends a test dose prior to starting I.V. mannitol therapy in patients with marked oliguria or suspected renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute renal failure (oliguria):",
"     </b>",
"     I.V.: Initial: 0.5-1 g/kg/dose infused over 2-6 hours; usual range: 0.25-2 g/kg/dose; may repeat dose every 4-6 hours;  do not repeat dose if oliguria persists.",
"     <b>",
"      Note:",
"     </b>",
"     Although FDA-labeled indications, the use of mannitol for the prevention of acute renal failure and/or promotion of diuresis is not routinely recommended (Kellum, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Test dose (to assess adequate renal function):",
"     </i>",
"     I.V.: 0.2 g/kg (maximum dose: 12.5 g) over 3-5 minutes to produce a urine flow of at least 1 mL/kg/hour for 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bronchial hyper-responsiveness assessment:",
"     </b>",
"     Children &ge;6 years and Adolescents: Oral inhalation: Administer in a stepwise fashion (measuring FEV",
"     <sub>",
"      1",
"     </sub>",
"     in duplicate at baseline and after each administration) until the patient has a positive response or 635 mg of mannitol has been administered (whichever comes first).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Positive test:",
"     </i>",
"     15% reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     from baseline or 10% incremental reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     between consecutive doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Negative test:",
"     </i>",
"     Administration of full dose (635 mg) without reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     sufficient to meet criteria for a positive test",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Administration should be as follows:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Stepwise Administration Schedule",
"     </caption>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose #",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cumulative Dose (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Capsules/Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         155",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         315",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         475",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         635",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intracranial pressure (ICP), reduction:",
"     </b>",
"     I.V.: Usual range: 0.25-1 g/kg/dose infused over 20-30 minutes; repeat as needed to maintain serum osmolality &lt;300-320 mOsm/kg (Bratton, 2007; Hegenbarth, 2008; Kochanek, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer&rsquo;s labeling allows for higher single doses up to 2 g/kg/dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intraocular pressure (IOP), reduction:",
"     </b>",
"     I.V.: 1-2 g/kg/dose",
"     <b>",
"      or",
"     </b>",
"     30-60 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose infused over 30-60 minutes administered 1-1.5 hours prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      IOP (traumatic hyphema), reduction:",
"     </b>",
"     I.V.: 1.5 g/kg/dose infused over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bronchial hyper-responsiveness, assessment:",
"     </b>",
"     Inhalation: Administer in a stepwise fashion (measuring FEV",
"     <sub>",
"      1",
"     </sub>",
"     in duplicate at baseline and after each administration) until the patient has a positive response or 635 mg of mannitol has been administered (whichever comes first).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Positive test:",
"     </i>",
"     15% reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     from baseline or 10% incremental reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     between consecutive doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Negative test:",
"     </i>",
"     Administration of full dose (635 mg) without reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     sufficient to meet criteria for a positive test",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Administration should be as follows:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Stepwise Administration Schedule",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose #",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cumulative Dose (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Capsules/Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         155",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         315",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         475",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         635",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 x 40 mg caps",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     <b>",
"      Increased intracranial pressure (ICP), cerebral edema:",
"     </b>",
"     I.V.: 0.25-1 g/kg/dose; may repeat every 6-8 hours as needed (Bratton, 2007; Kochanek, 2012); maintain serum osmolality &lt;300-320 mOsm/kg (Kochanek, 2012; Rabinstein, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Intraocular pressure (IOP), reduction:",
"     </b>",
"     I.V.: 0.25-2 g/kg infused over 30-60 minutes administered 1-1.5 hours prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      IOP (traumatic hyphema), reduction:",
"     </b>",
"     I.V.: 1.5 g/kg infused over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Transurethral irrigation:",
"     </b>",
"     Topical: Use 5% urogenital solution as required for irrigation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for renal impairment:",
"     </b>",
"     Contraindicated in severe renal impairment. Use with caution in patients with underlying renal disease. May be used to reduce the incidence of acute tubular necrosis when administered prior to revascularization during kidney transplantation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for hepatic impairment:",
"     </b>",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 20% [200 mg/mL] (250 mL, 500 mL); 25% [250 mg/mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Osmitrol: 5% [50 mg/mL] (1000 mL); 10% [100 mg/mL] (500 mL); 15% [150 mg/mL] (500 mL); 20% [200 mg/mL] (250 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 25% [250 mg/mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation [capsule/kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aridol&trade;: 0 mg (1s) [empty], 5 mg (1s), 10 mg (1s), 20 mg (1s), 40 mg (15s) (19s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, genitourinary irrigation: 5% [50 mg/mL] (2000 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes powder for inhalation",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation: For irrigation only; not for injection: Administer using only the appropriate transurethral urologic instrumentation. Do not warm above 66&deg;C (150&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Do not administer I.M. or SubQ. In-line filter set (&le;5 micron) should always be used for mannitol infusion with concentrations &ge;20%; maximum concentration for administration: 25%. Inspect for crystals prior to administration; if crystals are present, redissolve by warming solution. Do not administer with blood; crenation and agglutination of red blood cells may occur. pH: 4.5-7. Infusion rate is dependent upon indication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute renal failure: Administer over 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cerebral edema or increased intracranial pressure: Administer over 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Test dose (for oliguria): Administer over 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhalation (Aridol&trade;): Administer using supplied single patient use inhaler; do not puncture capsule more than once; do not swallow capsules. A nose clip may be used if preferred. The patient should exhale completely, followed by a controlled rapid deep inspiration from the device; hold breath for 5 seconds and exhale through the mouth. Measure FEV",
"     <sub>",
"      1",
"     </sub>",
"     in duplicate 60 seconds after inhalation; repeat process until positive response or full dose (635 mg) has been administered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F191322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR, NS, R.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bivalirudin, cisatracurium, cladribine, docetaxel, doripenem, etoposide phosphate, fenoldopam, fludarabine, fluorouracil, gallium nitrate, gemcitabine, hetastarch in lactate electrolyte injection (Hextend&reg;), idarubicin, linezolid, melphalan, ondansetron, oxaliplatin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, propofol, remifentanil, sargramostim, telavancin, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, doxorubicin liposome, filgrastim, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store intact vials at room temperature 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); store flexible container at 25&deg;C (77&deg;F); excursions permitted up to 40&deg;C (104&deg;F); protect parenteral dosage forms from freezing; avoid excessive heat. Mannitol preparations with concentrations &ge;15% may crystallize at low temperatures; do not use solutions that contain crystals; some products may be warmed in a hot water bath and shaken vigorously to resolubilize crystals (see product information for brand-specific instructions); solutions should be cooled to body temperature before using; incompatible with strongly acidic or alkaline solutions; potassium chloride or sodium chloride may cause precipitation of mannitol 20% or 25% solution. Discard unused portion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation: Store at room temperature 25&deg;C (77&deg;F); excursions permitted to 40&deg;C (104&deg;F). Avoid excessive heat; do not warm above 66&deg;C (150&deg;F). Do not freeze. Contains no antimicrobial or bacteriostatic agents; contents should be used promptly after opening to minimize the possibility of bacterial growth or pyrogen formation; discard unused portion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for inhalation: Store at &lt;25&deg;C (&lt;77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not refrigerate or freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Reduction of increased intracranial pressure (ICP) associated with cerebral edema and increased intraocular pressure (IOP) [FDA approved in pediatric patients (age not specified) and adults]; promotion of urinary excretion of toxic substances and diuresis in the prevention and/or treatment of oliguria or anuria due to acute renal failure [FDA approved in pediatric patients (age not specified) and adults].",
"     <b>",
"      Note:",
"     </b>",
"     Although FDA-labeled indications, the use of mannitol for the prevention of acute renal failure and/or promotion of diuresis is not routinely recommended (Kellum, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation solution, genitourinary: Irrigation in transurethral prostatic resection or other transurethral surgical procedures (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhalation powder: Assessment of bronchial hyper-responsiveness (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Osmitrol&reg; may be confused with esmolol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhalation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea, retching, throat irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngolaryngeal pain, rhinorrhea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: FEV",
"     <sub>",
"      1",
"     </sub>",
"     decreased, gagging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain, CHF, circulatory overload, hyper-/hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Chills, convulsions, dizziness, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Bullous eruption, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid and electrolyte imbalance, dehydration and hypovolemia secondary to rapid diuresis, hyperglycemia, hypernatremia, hyponatremia (dilutional), hyperosmolality-induced hyperkalemia, metabolic acidosis (dilutional), osmolar gap increased, water intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Dysuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Pain, thrombophlebitis, tissue necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Renal: Acute renal failure, acute tubular necrosis (adult dose &gt;200 g/day; serum osmolality &gt;320 mOsm/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pulmonary edema, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Hypersensitivity to mannitol or any component; severe renal disease (anuria); severe dehydration; active intracranial bleeding except during craniotomy; severe pulmonary edema or congestion; progressive heart failure, pulmonary congestion, or renal dysfunction after mannitol administration (or history thereof)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation solution, genitourinary: Hypersensitivity to mannitol or any component; anuria; use as an injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for inhalation: Hypersensitivity to mannitol, gelatin, or any component; conditions that may be compromised by induced bronchospasm or repeated spirometry (eg, aortic or cerebral aneurysm, uncontrolled hypertension, recent MI or cerebral vascular accident)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14784338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution  in patients with renal impairment; intravenous mannitol should not be administered until adequacy of renal function and urine flow is established; may use 1-2 test doses to assess renal response. Use with caution in patients with hyponatremia; the shift of sodium-free intracellular fluid into the extracellular space that occurs after mannitol infusion may lower serum sodium further.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In patients being treated for cerebral edema, mannitol may accumulate in the brain (causing rebound increases in intracranial pressure); this may occur if brain tissue is injured or if mannitol is used or circulating for extended periods of time (eg, as with continuous infusion); thus, intermittent boluses are preferred. If hypotension occurs, monitor cerebral perfusion pressure to ensure it is adequate. Cardiovascular status should also be evaluated; significant extracellular fluid expansion may occur and lead to fulminant congestive heart failure. Do not administer electrolyte-free mannitol solutions with blood. Mannitol is a vesicant; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Irrigation solution should be used with caution in severe cardiopulmonary or renal dysfunction. Irrigating fluids used during transurethral prostatectomy may be absorbed systemically; the resultant osmotic diuresis may significantly affect cardiopulmonary and renal dynamics.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14784326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of I.V. mannitol can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Monitor and correct electrolyte disturbances; adjust dose to avoid dehydration. May cause severe osmotic nephrosis and/or renal dysfunction especially with high doses; use with caution in patients taking other nephrotoxic agents, with sepsis, or pre-existing renal disease. To minimize adverse renal effects, adjust dosage to keep serum osmolality less than 320 mOsm/L; discontinue if evidence of acute tubular necrosis occurs. May cause progressive heart failure or pulmonary congestion after administration; if occurs, subsequent use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Mannitol may increase cerebral blood flow, increase the risk of postoperative bleeding in neurosurgical patients, and worsen intracranial hypertension in children who develop generalized cerebral hyperemia during the first 24-48 hours after traumatic brain injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Powder for inhalation (Aridol&trade;): Mannitol may cause severe bronchospasm. Bronchial challenge testing should be for diagnostic purposes only and performed by trained professionals; patients should not be left unattended during testing. Do not use in patients with clinically apparent asthma or very low baseline pulmonary function (eg, FEV",
"     <sub>",
"      1",
"     </sub>",
"     &lt;1-1.5 L or &lt;70% of the predicted values). Medications (eg, short-acting inhaled beta-agonist) and equipment for the treatment of severe bronchospasm should be readily available during use.",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients with conditions that may increase sensitivity to bronchoconstriction (eg, severe cough, ventilatory impairment, spirometry-induced bronchoconstriction, hemoptysis of unknown origin, pneumothorax; recent abdominal, thoracic, or intraocular surgery; unstable angina, active upper or lower respiratory tract infection). Patients who have &ge;10% reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     on administration of the 0 mg capsule, patients with a positive response to bronchial challenge testing, or patients who develop significant respiratory symptoms should be treated with a short-acting inhaled beta-agonist and monitored until full recovery to baseline; discontinue further testing. Bronchial challenge testing should not be performed in children &lt;6 years of age as these patients are unable to provide reliable spirometric results.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F854599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal function, daily fluid intake and output, serum electrolytes, serum and urine osmolality; for treatment of elevated intracranial pressure, maintain serum osmolality &lt;300-320 mOsm/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bronchial challenge test: Standard spirometry prior to bronchial challenge test; FEV",
"     <sub>",
"      1",
"     </sub>",
"     in duplicate 60 seconds after administration of each step of test",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces an osmotic diuresis by increasing the osmotic pressure of glomerular filtrate, which inhibits tubular reabsorption of water and electrolytes and increases urinary output. Mechanism of action in reduction of intracranial pressure (ICP) is controversial; however, it is thought that mannitol reduces ICP by causing an immediate plasma expansion that reduces blood viscosity and transiently increases cerebral blood flow and oxygen transport. This in turn reduces cerebral blood volume and ICP. Furthermore, mannitol reduces ICP by withdrawing water from the brain parenchyma and moving it into the extracellular compartment (systemic circulation), then excreting the water in the urine (Allen, 2009; Bratton, 2007; Miller, 2010). The mechanism of action for producing bronchoconstriction is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bronchospasm, challenge: Inhalation: Within 1 minute if positive response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Diuresis: I.V.: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ICP reduction: I.V.: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ICP reduction: I.V.: 3-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 34.3 L; remains confined to extracellular space; does not penetrate blood-brain barrier except in very high concentrations or with acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal amounts in the liver to glycogen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Inhalation: Absolute: 59% (relative to oral administration: 96%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection: 0.25-1.7 hours; 6-36 hours in renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: 4.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Inhalation: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~55% to 87% as unchanged drug by glomerular filtration)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/34/29221?source=see_link\">",
"      see \"Mannitol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth. Report immediately any nausea, dizziness, respiratory difficulty, chest pain, or pain at infusion site.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Approximate osmolarity: Mannitol 20%: 1100 mOsm/L; mannitol 25%: 1375 mOsm/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bronchial challenge testing: The dose of inhaled mannitol which causes a 15% reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"     is expressed as PD",
"     <sub>",
"      15",
"     </sub>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allen CH and Ward JD, \"An Evidence-Based Approach to Management of Increased Intracranial Pressure,\"",
"      <i>",
"       Crit Care Clin",
"      </i>",
"      , 1998, 14(3):485-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/9700443/pubmed\" id=\"9700443\" target=\"_blank\">",
"        9700443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andreoli SP, \"Acute Renal Failure in the Newborn,\"",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 2004, 28(2):112-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/15200250/pubmed\" id=\"15200250\" target=\"_blank\">",
"        15200250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratton SL, Chestnut RM, Ghajar J, et al, \"Guidelines for the Management of Severe Traumatic Brain Injury. II. Hyperosmolar Therapy,\"",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):14-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/17511539/pubmed\" id=\"17511539\" target=\"_blank\">",
"        17511539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldmann E, et al, \"Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chua AN and Sarwal MM, \"Acute Renal Failure Management in the Neonate,\"",
"      <i>",
"       NeoReviews",
"      </i>",
"      , 2005, 6:e369-76.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crouch ER Jr and Crouch ER, \"Management of Traumatic Hyphema: Therapeutic Options,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 1999, 36(5):238-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/10505828/pubmed\" id=\"10505828\" target=\"_blank\">",
"        10505828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kellum JA, Cerda J, Kaplan LJ, et al, \"Fluids for Prevention and Management of Acute Kidney Injury,\"",
"      <i>",
"       Int J Artif Organs",
"      </i>",
"      , 2008, 31(2):96-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/18311727/pubmed\" id=\"18311727\" target=\"_blank\">",
"        18311727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, \"Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents--Second Edition,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 13(Suppl 1):1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller RD,",
"      <i>",
"       Miller&rsquo;s Anesthesia",
"      </i>",
"      , 7th ed, Philadelphia PA: Churchill Livingstone, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabinstein AA, \"Treatment of Cerebral Edema,\"",
"      <i>",
"       Neurologist",
"      </i>",
"      , 2006, 12(2):59-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/60/43975/abstract-text/16534443/pubmed\" id=\"16534443\" target=\"_blank\">",
"        16534443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12570 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C815FD8784-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43975=[""].join("\n");
var outline_f42_60_43975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12595457\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191286\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191287\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053764\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675191\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053756\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191267\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191253\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053768\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191322\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053759\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053767\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191324\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191321\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053772\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14784338\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14784326\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299644\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191261\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191263\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854599\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053763\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053755\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053770\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053771\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053761\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053773\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12570\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12570|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=related_link\">",
"      Mannitol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/34/29221?source=related_link\">",
"      Mannitol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43976="Neuromuscular weakness related to critical illness";
var content_f42_60_43976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuromuscular weakness related to critical illness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43976/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43976/contributors\">",
"     David Lacomis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43976/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43976/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43976/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/60/43976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular weakness is a common occurrence in patients who are critically ill, developing in &ge;25 percent of patients who are in the intensive care unit (ICU) and ventilated for at least seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/1\">",
"     1",
"    </a>",
"    ]. Weakness is partly a consequence of improved survival in patients with multiorgan failure and sepsis, but is also a consequence of treatments administered in the ICU, including intravenous glucocorticoids and sometimes paralytic agents.",
"   </p>",
"   <p>",
"    Neuromuscular weakness in the ICU is most often due to critical illness myopathy or to critical illness polyneuropathy. This topic will review the peripheral neuromuscular disorders of critical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a critically ill patient who develops flaccid generalized weakness, the major considerations in the differential diagnosis are critical illness myopathy and critical illness polyneuropathy, or a combination of the two. Prolonged neuromuscular junction blockade is rare. Each of these disorders is discussed in detail below.",
"   </p>",
"   <p>",
"    Other acute and subacute myopathies can occur in critically ill patients, including rhabdomyolysis and cachectic myopathy. In addition, rare acute neuropathies such as Guillain-Barr&eacute; syndrome can also develop in the ICU.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some critically ill patients develop rhabdomyolysis due to their illness or medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral, bacterial, and fungal infections",
"     </li>",
"     <li>",
"      Neuroleptic malignant syndrome or serotonin syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Medications such as neuroleptics, anticholinergics, amphotericin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      , and others",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with rhabdomyolysis, serum creatine kinase levels are often markedly elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/2\">",
"     2",
"    </a>",
"    ]. There may be mild to moderate weakness with muscle swelling and myalgias, but there is usually only a mild degree of muscle necrosis histologically, and the electromyography (EMG) abnormalities can be minimal with only mild fibrillation potential activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cachectic myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with critical illness can develop a subacute myopathy due to protein catabolism and disuse, a disorder that has been termed cachectic myopathy.",
"   </p>",
"   <p>",
"    In cachectic myopathy, there is proximal-predominant weakness with muscle wasting, a normal serum creatine kinase, laboratory evidence of malnutrition, normal or mildly \"myopathic\" motor unit potential changes on EMG without fibrillation potentials, and type 2 muscle fiber atrophy histologically. Cachectic myopathy is a diagnosis of exclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute inflammatory demyelinating polyneuropathy (Guillain-Barr&eacute; syndrome) is an uncommon occurrence in critically ill patients. Patients with Guillain-Barr&eacute; syndrome typically have features of a demyelinating polyneuropathy on nerve conduction studies and a high cerebrospinal fluid protein concentration. Other features may overlap with critical illness polyneuropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CRITICAL ILLNESS MYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common form of intensive care unit (ICU)-acquired myopathy is critical illness myopathy (CIM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This disorder is also known by other names, including acute quadriplegic myopathy and thick filament myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epidemiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prospective studies, approximately one-third of patients with status asthmaticus or chronic obstructive pulmonary disease and 7 percent who receive a liver transplant develop CIM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Patients with other critical illnesses, such as acute respiratory distress syndrome, may also be affected. Each of these disorders is typically associated with intravenous (IV) glucocorticoid therapy.",
"   </p>",
"   <p>",
"    The strongest risk factor for CIM is the use of IV glucocorticoids in the ICU setting, and there is some correlation between the likelihood of occurrence and severity of disease with glucocorticoid dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/7,8,10-12\">",
"     7,8,10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, rare patients with CIM have not been exposed to IV glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Another potential risk factor for CIM is the use of various types of paralytic agents.",
"   </p>",
"   <p>",
"    Associated and perhaps triggering factors may include a higher illness severity index, hyperglycemia, hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/15\">",
"     15",
"    </a>",
"    ], and possibly the systemic inflammatory response syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical features of CIM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical illness myopathy usually begins several days after IV glucocorticoid treatment is initiated. The time of onset of the myopathy may not be known in patients who are comatose or encephalopathic.",
"   </p>",
"   <p>",
"    The most common presenting features of CIM are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/9,11-14,16-18\">",
"     9,11-14,16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flaccid quadriparesis that may affect proximal more than distal muscles",
"     </li>",
"     <li>",
"      Failure to wean from mechanical ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Facial muscle weakness is also relatively common, but extraocular muscle weakness rarely occurs.",
"   </p>",
"   <p>",
"    In the ICU setting, it is often difficult to assess sensation. If assessable, sensation should be normal. Patients should at least grimace to pain stimuli even when they are encephalopathic. Deep tendon reflexes may be normal or attenuated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory and electrodiagnostic findings in CIM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study of 25 patients with status asthmaticus who were treated with IV glucocorticoids, nine patients had clinically detectable myopathy, while 19 had an elevated serum creatine kinase (CK), with a median value of 1575",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    (range 66 to 7430",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/8\">",
"     8",
"    </a>",
"    ]. The increase in serum CK peaked around four days after initial treatment with glucocorticoids, and lasted for as long as 16 days.",
"   </p>",
"   <p>",
"    In retrospective series of patients with CIM, approximately one-half had elevations in CK. It is possible that elevated CK levels would have been identified in more patients if the CK measurements had occurred within the appropriate time window.",
"   </p>",
"   <p>",
"    The major nerve conduction findings of CIM are normal to low motor amplitudes with occasional broadening of the compound muscle action potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Phrenic motor amplitudes may also be low. Sensory responses are normal or only mildly reduced, unless there is a coexisting polyneuropathy. Rarely, neuromuscular junction blockade occurs and can be identified transiently via low rates of repetitive stimulation that reveal a decremental response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Needle examination often but not uniformly reveals fibrillation potential activity. Depending upon the degree of weakness, observation of the recruitment of motor unit potentials (MUPs) may be difficult. When it is possible to evaluate, recruitment tends to be early. MUPs are short in duration, low in amplitude, and sometimes polyphasic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some muscles exhibit electrical inexcitability to direct muscle stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This inexcitability is due to a defect in muscle membrane depolarization, which may be related to increased inactivation of sodium channels at the resting potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Direct muscle stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct muscle stimulation is especially useful in differentiating CIM from motor axonopathy and can be incorporated into a diagnostic algorithm (",
"    <a class=\"graphic graphic_table graphicRef76493 \" href=\"mobipreview.htm?38/3/38971\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/24\">",
"     24",
"    </a>",
"    ]. However, some patients also have a coexisting peripheral neuropathy.",
"   </p>",
"   <p>",
"    Direct muscle stimulation has been performed using a stimulating monopolar needle electrode or surface electrode placed just proximal to the tendon insertion. The tibialis anterior muscle is commonly tested. After obtaining a muscle twitch, a recording needle electrode is placed in the center of the muscle proximal to the site of stimulation, and the maximal muscle-stimulated compound muscle action potential (mCMAP) is recorded. The recording electrode is kept in place and the appropriate nerve undergoes surface stimulation, recording a nerve-evoked compound muscle action potential (nCMAP). The nCMAP to mCMAP ratio is calculated; a value &gt;0.5 suggests impaired muscle membrane excitability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/22,25\">",
"     22,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathology and pathogenesis of CIM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major histopathologic finding in CIM is relatively selective loss of myosin, which can be identified as a lack of reactivity to myosin ATPase in non-necrotic fibers. This finding can be confirmed with immunohistochemical studies for myosin and by utilizing electron microscopy to identify loss of thick filaments.",
"   </p>",
"   <p>",
"    There is usually atrophy of myofibers, type 2 more than type 1. There is often evidence of myofibrillar disorganization, which may be partly manifested as abnormal basophilic stippling on hematoxylin and eosin stains, purplish staining with Gomori trichrome, and irregular clumping of the reaction product with NADH-TR. Some degree of necrosis may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/11,26,27\">",
"     11,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, there is evidence that several processes are involved in the pathogenesis of CIM, including upregulation of calpain, an increase in muscle apoptosis, activation of the proteosome ubiquitin-degradative system, and upregulation of the transforming growth",
"    <span class=\"nowrap\">",
"     factor-beta/mitogen-activated",
"    </span>",
"    protein kinase pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxidative stress may also play a role in the development of CIM, as illustrated by the finding that sarcolemmal immunostaining of the nitric oxide synthase isoform NOS1 was reduced or absent in six patients with CIM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/29\">",
"     29",
"    </a>",
"    ]. While the significance of this finding is not clear, it is hypothesized that the loss of sarcolemmal NOS1 could lead to muscle fiber inexcitability by reducing nitric oxide release at the muscle membrane.",
"   </p>",
"   <p>",
"    A steroid-denervation animal model reproduces the histopathologic and electrophysiologic findings of CIM in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/30\">",
"     30",
"    </a>",
"    ] and suggests that a deleterious interaction between glucocorticoids and denervation leads to a depletion of the mRNA for myosin, and to muscle atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Muscle sodium channel properties were also evaluated in a chronic sepsis animal model produced by needle perforation after cecal ligature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/32\">",
"     32",
"    </a>",
"    ]. Patch clamp technique revealed decreased sodium current that could lead to muscle inexcitability. However, muscle histopathology and nerve conduction studies were not assessed in this model, so it is unknown if there was neuropathy or structural myopathy with myosin loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnosis of CIM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CIM is suspected in patients who have the clinical features cited above, particularly flaccid muscle weakness and ventilatory failure, in the setting of critical illness. Exposure to intravenous glucocorticoids is an important clue. An elevation in serum creatine kinase is usually present but, among patients treated with intravenous glucocorticoids, can occur in the absence of CIM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features of CIM'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Critical illness myopathy can be distinguished from critical illness polyneuropathy (CIP) if preservation of sensory function (indicative of the former) can be demonstrated. However, sensory evaluation can be difficult in critically ill patients, particularly when obtunded, comatose, or intubated, and it may be difficult to distinguish CIM from CIP on the basis of clinical features and neurologic examination findings alone. Furthermore, some patients have features of combined CIM and CIP. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical features of CIP'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Combined critical illness myopathy and polyneuropathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with appropriate clinical features, the diagnosis of CIM can sometimes be confirmed by electrophysiologic testing with nerve conduction studies (NCS) and electromyography (EMG). Muscle biopsy can provide additional diagnostic information but is rarely performed, unless another treatable condition, such as an inflammatory myopathy, is in the differential diagnosis.",
"   </p>",
"   <p>",
"    The major diagnostic features of CIM are (",
"    <a class=\"graphic graphic_table graphicRef76493 \" href=\"mobipreview.htm?38/3/38971\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory nerve amplitudes &gt;80 percent of the lower limit of normal in two or more nerves on NCS",
"     </li>",
"     <li>",
"      Needle EMG with short-duration, low-amplitude MUPs with early or normal full recruitment, with or without fibrillation potentials",
"     </li>",
"     <li>",
"      Absence of a decremental response on repetitive nerve stimulation",
"     </li>",
"     <li>",
"      Muscle histopathologic findings of myopathy with myosin loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive diagnostic features of CIM are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motor amplitudes &lt;80 percent of the lower limit of normal in two or more nerves without conduction block on NCS",
"     </li>",
"     <li>",
"      Elevated serum CK (best assessed in the first week of illness)",
"     </li>",
"     <li>",
"      Muscle inexcitability on direct muscle stimulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment and prognosis of CIM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical illness myopathy is usually reversible over weeks to months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/33\">",
"     33",
"    </a>",
"    ], but leads to prolonged ICU stays and increased length of hospital stay overall. The major goal is to avoid its occurrence. Treatment of CIM is directed toward discontinuation or reduction of glucocorticoids as soon as possible, aggressive management of medical conditions, avoidance of additional complications such as venous thrombosis, and rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not established, two studies have reported that intensive insulin therapy (target blood glucose 80 to 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.4 to 6.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    may lower the incidence of CIM and CIP among critically ill patients who remain in the intensive care unit for seven or more days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These studies are limited by methodologic issues; both were subgroup analyses, and the diagnosis of",
"    <span class=\"nowrap\">",
"     CIP/CIM",
"    </span>",
"    was made based upon EMG criteria only. In addition, tight control of hyperglycemia in the intensive care unit is controversial because of concern that it may result in increased mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link&amp;anchor=H5#H5\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Research regarding methods to block the occurrence of CIM is highly desirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CRITICAL ILLNESS POLYNEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second neuromuscular condition that is commonly acquired in the intensive care unit (ICU) is critical illness polyneuropathy (CIP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/6,37-39\">",
"     6,37-39",
"    </a>",
"    ]. This disorder was first recognized clinically in the late 1970s and 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Association with sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical illness polyneuropathy appears to be a common complication of severe sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/41-43\">",
"     41-43",
"    </a>",
"    ] and is thought to represent a neurologic manifestation of the systemic inflammatory response syndrome (SIRS). There is some correlation with elevations in blood glucose and reductions in serum albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of axonal injury in CIP is unknown. However, speculation focuses on injury to the microcirculation of distal nerves, causing ischemia and axonal degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/16,43\">",
"     16,43",
"    </a>",
"    ]. During the early stages of sepsis, electrical inexcitability due to sodium channel inactivation may be present in otherwise intact nerves. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Combined critical illness myopathy and polyneuropathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The association of sepsis with CIP is illustrated by a prospective report that assessed electrophysiologic and clinical data from 43 patients an average of 28 days after the onset of sepsis and multiorgan failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/38\">",
"     38",
"    </a>",
"    ]. An axonal polyneuropathy was present in 30 patients (70 percent), 15 of whom also had clinical evidence of generalized muscle dysfunction, characterized by limb muscle weakness, reduced or absent deep tendon reflexes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed weaning from mechanical ventilation. Three severely affected patients were unable to move any of their extremities, failed to improve, and ultimately died.",
"   </p>",
"   <p>",
"    Many patients with severe sepsis who develop neuromuscular weakness in the ICU have a combination of CIM and CIP. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Combined critical illness myopathy and polyneuropathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical features of CIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical illness polyneuropathy usually occurs in patients who are in the ICU for one or especially two weeks or more. The clinical features can overlap with those of critical illness myopathy. In many cases, patients with CIP require prolonged weaning from mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/42,44\">",
"     42,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients manifest a sensorimotor polyneuropathy characterized clinically by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limb muscle weakness and atrophy",
"     </li>",
"     <li>",
"      Reduced or absent deep tendon reflexes",
"     </li>",
"     <li>",
"      Loss of peripheral sensation to light touch and pin prick",
"     </li>",
"     <li>",
"      Relative preservation of cranial nerve function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While patients with CIP may exhibit distal sensory loss, this finding can only be assessed if a reliable sensory examination is possible in an awake, alert, and cooperative patient. However, encephalopathy is a frequent accompaniment of critical illness, and often precludes a detailed sensory examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory and electrodiagnostic findings in CIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies in patients with CIP typically reveal low motor and sensory amplitudes, and over time fibrillation potentials will be evident on electromyography (EMG) needle examination. Phrenic motor amplitudes are commonly reduced. Some patients appear to have predominant motor involvement, but myopathy should be excluded in such patients. The serum CK levels are normal and muscle biopsy findings are those of neurogenic atrophy. Cerebrospinal fluid protein levels are usually normal.",
"   </p>",
"   <p>",
"    In patients with CIP, direct needle stimulation of muscle elicits a relatively higher amplitude response compared with the response recorded from muscle after nerve stimulation. In contrast, in critical illness myopathy, there are proportionally low direct muscle- and nerve-evoked responses. The technique of direct muscle stimulation is discussed in detail above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Direct muscle stimulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnosis of CIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CIP is suspected in patients who have the clinical features of the disorder. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical features of CIP'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As with critical illness myopathy (CIM), it is often difficult to distinguish CIP from CIM or from combined CIM and CIP on the basis of clinical features and neurologic examination findings alone. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features of CIM'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Combined critical illness myopathy and polyneuropathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following diagnostic criteria for CIP are well established (",
"    <a class=\"graphic graphic_table graphicRef55570 \" href=\"mobipreview.htm?32/49/33563\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Setting of critical illness, particularly if complicated by sepsis, multiorgan failure, and the systemic inflammatory response syndrome",
"     </li>",
"     <li>",
"      Difficulty weaning from ventilator that is not related to cardiopulmonary causes",
"     </li>",
"     <li>",
"      Possible limb weakness",
"     </li>",
"     <li>",
"      Electrophysiologic evidence of axonal motor and sensory polyneuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is no consensus on specific electrodiagnostic and laboratory criteria for CIP, the following features favor the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory and motor nerve amplitudes &lt;80 percent of the lower limit of normal in two or more nerves on nerve conduction studies",
"     </li>",
"     <li>",
"      Absence of conduction block or prolongation of F-waves",
"     </li>",
"     <li>",
"      Needle EMG with reduced recruitment of normal motor unit potentials (MUPs) (early) followed by fibrillation potentials and reduced recruitment of long-duration, high-amplitude MUPs (after weeks)",
"     </li>",
"     <li>",
"      Absence of a decremental response on repetitive nerve stimulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive diagnostic features of CIP are a normal CSF protein and a normal serum creatine kinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment and prognosis of CIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In survivors of CIP with mild or moderate nerve injury, recovery of muscle strength generally occurs over weeks to months. However, electrodiagnostic testing may demonstrate residual nerve dysfunction several years after initial presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with severe CIP may remain quadriplegic.",
"   </p>",
"   <p>",
"    As noted above, there is evidence that intensive insulin therapy (target blood glucose 80 to 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.4 to 6.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    may lower the incidence of CIM and CIP among critically ill patients who remain in the intensive care unit for seven or more days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These studies are limited by methodologic issues. In addition, tight control of hyperglycemia in the intensive care unit is controversial because of concern that it may result in increased mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link&amp;anchor=H5#H5\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with CIM, treatment of CIP is supportive and includes aggressive management of sepsis and underlying medical conditions, avoidance of additional complications such as venous thrombosis, and rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMBINED CRITICAL ILLNESS MYOPATHY AND POLYNEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with neuromuscular weakness in the ICU sometimes have a combination of both critical illness myopathy (CIM) and critical illness polyneuropathy (CIP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/6,46,47\">",
"     6,46,47",
"    </a>",
"    ]. This combined disorder has also been termed critical illness polyneuromyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of combined CIM and CIP were illustrated by a prospective longitudinal cohort study of 48 patients who had baseline neurologic examinations and nerve conduction studies (NCS) within 72 hours of developing severe sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/48\">",
"     48",
"    </a>",
"    ]. Electromyography was performed for patients who developed clinical weakness or had a &ge;30 percent reduction in nerve conduction response amplitudes. Clinical and electrophysiologic examinations were repeated weekly for the duration of the ICU stay.",
"   </p>",
"   <p>",
"    The following observations were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal NCS were present at baseline in 63 percent of patients, and an abnormality on baseline NCS was significantly associated with hospital mortality compared with a normal baseline NCS (55 versus 0 percent, respectively).",
"     </li>",
"     <li>",
"      In 20 patients who remained in the ICU long enough to have serial NCS, neuromuscular dysfunction developed in 10 patients (50 percent). Electrophysiologic evidence of both CIM and CIP was present in 8 of 10 patients with neuromuscular dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The investigators hypothesized that sepsis may be a common pathologic mechanism underlying the development of both CIM and CIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/48\">",
"     48",
"    </a>",
"    ]. Although not established, they further speculated that sepsis may trigger reversible but prolonged electrical inexcitability of nerve, similar in concept to the electrical inexcitability of muscle that has been observed in patients with CIM. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Laboratory and electrodiagnostic findings in CIM'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In an extension of this study, four of nine patients with neuropathy survived and were followed until they recovered from sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/49\">",
"     49",
"    </a>",
"    ]. In three survivors with electrodiagnostic studies, there was rapid improvement in neuropathy during the early period of recovery from critical illness, as demonstrated by increases in both sensory and motor nerve response amplitudes. In a septic rat model, the same investigators found reduced mixed motor and sensory tail nerve amplitudes and reduced excitability in dorsal root sensory axons via intracellular recordings. These experiments indicated that sodium channels were inactivated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The investigators interpreted these data as evidence of either a novel neuropathy in critical illness or an acquired sodium channelopathy that causes neuropathy early in the course of CIP and may be reversible without progressing to axonal degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/49\">",
"     49",
"    </a>",
"    ]. In conjunction with studies in CIM, the data further suggest that the acquired sodium channelopathy in critical illness affects different sodium channel isoforms in both nerve and muscle.",
"   </p>",
"   <p>",
"    Another study of 92 patients who had normal nerve conductions at 24 hours after intensive care unit admission showed that serial electrodiagnostic studies are helpful in predicting development of CIM",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/50\">",
"     50",
"    </a>",
"    ]. A reduction of &gt;25 percent in the peroneal motor amplitude (compound muscle action potential) was the most useful measure, with the best combination of sensitivity and specificity (100 and 67 percent, respectively). In some patients, the transition to",
"    <span class=\"nowrap\">",
"     CIM/CIP",
"    </span>",
"    was abrupt (ie, within 24 hours). In others, it occurred over days. In this study, CIM",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CIP were associated with multiorgan failure but not with a systemic inflammatory response syndrome, sepsis, drugs, or nutrition. The simplified electrophysiologic test used in this study was not able to distinguish CIM from CIP, and the investigators suggest performing a complete electrodiagnostic evaluation for patients with a &gt;25 percent reduction from baseline in the peroneal compound muscle action potential on two consecutive days.",
"   </p>",
"   <p>",
"    It does seem likely that reduction of nerve excitability (ie, inactivation of sodium channels) and axon degeneration (the currently accepted mechanism of CIP) may represent different ends of a single pathophysiologic spectrum that varies according to the severity of the inflammatory process in CIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/51\">",
"     51",
"    </a>",
"    ], and that muscle membrane inexcitability, myosin loss, and muscle necrosis comprise the pathophysiologic spectrum in CIM.",
"   </p>",
"   <p>",
"    For patients with combined CIM and CIP, muscle histopathology may be required to confirm the presence of myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROLONGED NEUROMUSCULAR JUNCTION BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare disorder occurring in the ICU is prolonged neuromuscular junction blockade. This disorder is related to prolonged use (days) of paralytic agents, often in the setting of renal or hepatic insufficiency, leading to prolonged circulation of drug metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. These curare-like paralytic agents bind reversibly to acetylcholine receptors on the motor end-plates of neuromuscular junctions, thereby inhibiting neuromuscular transmission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The commonly used aminosteroid blocking agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    , are normally cleared from the circulation within several hours, primarily by the liver. However, in patients with decreased renal function (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    functionally active 3-hydroxy metabolites of these drugs accumulate and persist in the blood. As a result, neuromuscular blockade may continue for as long as one week after drug administration is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients have flaccid areflexic tetraplegia. Train-of-four stimulation (a test commonly used by anesthesiologists to assess recovery from acute blockade during surgery) may detect a major neuromuscular junction defect, but formal repetitive nerve stimulation is required for confirmation. Transient improvement in muscle strength after administration of an anticholinesterase reversing agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    supports prolonged neuromuscular junction blockade as a cause of weakness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed reversal of neuromuscular blockade can be prevented by avoiding aminosteroid blocking drugs in favor of benzylisoquinoline agents (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    ) in patients who have renal insufficiency. In contrast to the aminosteroid drugs, atracurium and its congeners (doxacurium,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"     cisatracurium",
"    </a>",
"    , and others) are degraded spontaneously to inactive metabolites in the blood at a rate unaffected by kidney, liver, or cardiovascular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43976/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular weakness is a common occurrence in patients who are critically ill and develops in approximately 25 percent or more of patients who are in the intensive care unit (ICU) and ventilated for seven or more days.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a critically ill patient who develops flaccid generalized weakness, the major considerations in the differential diagnosis are critical illness myopathy (CIM) and critical illness polyneuropathy (CIP), or a combination of the two. Other considerations in the differential include rhabdomyolysis, cachectic myopathy, and Guillain-Barr&eacute; syndrome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Critical illness myopathy (CIM) is the most common form of ICU-acquired myopathy (",
"      <a class=\"graphic graphic_table graphicRef76493 \" href=\"mobipreview.htm?38/3/38971\">",
"       table 1",
"      </a>",
"      ). The strongest risk factor for CIM is the use of intravenous (IV) glucocorticoids in the ICU setting. CIM usually begins several days or so after IV glucocorticoid treatment is initiated. The most common presenting features are flaccid quadriparesis and failure to wean from mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Critical illness myopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major electrophysiologic findings of CIM include normal to low-amplitude, often broad (long duration) motor responses and short-duration motor unit potentials coupled with normal or near-normal sensory potentials. Needle electromyography shows early or normal full recruitment. Some muscles exhibit electrical inexcitability to direct muscle stimulation. The major histopathologic findings are myopathy and myosin loss. Serum CK elevation is seen in approximately one-half of patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory and electrodiagnostic findings in CIM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CIM is usually reversible over weeks to months but it leads to prolonged ICU stays and increased length of hospital stay overall. Treatment is directed toward discontinuation or reduction of glucocorticoids as soon as possible. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment and prognosis of CIM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Critical illness polyneuropathy (CIP) is another common cause of neuromuscular weakness that is acquired in the ICU, most often as a complication of severe sepsis (",
"      <a class=\"graphic graphic_table graphicRef55570 \" href=\"mobipreview.htm?32/49/33563\">",
"       table 2",
"      </a>",
"      ). CIP is thought to represent a neurologic manifestation of the systemic inflammatory response syndrome. CIP is characterized clinically by limb muscle weakness and atrophy, reduced or absent deep tendon reflexes, loss of distal peripheral sensation, and relative preservation of cranial nerve function. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Critical illness polyneuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nerve conduction studies in patients with CIP typically reveal low motor and sensory amplitudes. Needle EMG may show fibrillation potentials in subacute to chronic patients. The serum CK levels are normal and muscle biopsy shows findings consistent with neurogenic atrophy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory and electrodiagnostic findings in CIP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In survivors of CIP with mild or moderate nerve injury, recovery of muscle strength generally occurs over weeks to months. Treatment of CIP is supportive. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment and prognosis of CIP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined CIM and CIP, sometimes called critical illness polyneuromyopathy, is increasingly recognized as a cause of neuromuscular weakness in the ICU. Sepsis and the systemic inflammatory response syndrome may be a common pathologic mechanism underlying the development of both CIM and CIP. Nerve conduction studies may be predictive of neuromuscular dysfunction as early as 72 hours after onset of critical illness. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Combined critical illness myopathy and polyneuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged neuromuscular junction blockade is a rare disorder related to prolonged use (days) of paralytic agents, often in the setting of renal or hepatic insufficiency, leading to prolonged circulation of drug metabolites. Affected patients have flaccid areflexic tetraplegia. Repetitive nerve stimulation is required for confirmation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prolonged neuromuscular junction blockade'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/1\">",
"      De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/2\">",
"      Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/3\">",
"      Al-Shekhlee A, Hachwi R, Jaberi MM, Katirji B. The electromyographic features of acute rhabdomyolysis. J Clin Neuromuscul Dis 2005; 6:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/4\">",
"      Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005; 32:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/5\">",
"      Koch S, Spuler S, Deja M, et al. Critical illness myopathy is frequent: accompanying neuropathy protracts ICU discharge. J Neurol Neurosurg Psychiatry 2011; 82:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/6\">",
"      Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 2011; 10:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/7\">",
"      Amaya-Villar R, Garnacho-Montero J, Garc&iacute;a-Garmend&iacute;a JL, et al. Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2005; 31:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/8\">",
"      Douglass JA, Tuxen DV, Horne M, et al. Myopathy in severe asthma. Am Rev Respir Dis 1992; 146:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/9\">",
"      Campellone JV, Lacomis D, Kramer DJ, et al. Acute myopathy after liver transplantation. Neurology 1998; 50:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/10\">",
"      Shee CD. Risk factors for hydrocortisone myopathy in acute severe asthma. Respir Med 1990; 84:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/11\">",
"      Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996; 40:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/12\">",
"      Panegyres PK, Squier M, Mills KR, Newsom-Davis J. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry 1993; 56:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/13\">",
"      Deconinck N, Van Parijs V, Beckers-Bleukx G, Van den Bergh P. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord 1998; 8:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/14\">",
"      Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997; 20:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/15\">",
"      Riggs JE, Pandey HK, Schochet SS Jr. Critical illness myopathy associated with hyperthyroidism. Mil Med 2004; 169:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/16\">",
"      Bolton CF, Young GB, Zochodne DW. The neurological complications of sepsis. Ann Neurol 1993; 33:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/17\">",
"      Hanson P, Dive A, Brucher JM, et al. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997; 20:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/18\">",
"      Zochodne DW, Ramsay DA, Saly V, et al. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve 1994; 17:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/19\">",
"      Goodman BP, Harper CM, Boon AJ. Prolonged compound muscle action potential duration in critical illness myopathy. Muscle Nerve 2009; 40:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/20\">",
"      Barohn RJ, Jackson CE, Rogers SJ, et al. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve 1994; 17:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/21\">",
"      Road J, Mackie G, Jiang TX, et al. Reversible paralysis with status asthmaticus, steroids, and pancuronium: clinical electrophysiological correlates. Muscle Nerve 1997; 20:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/22\">",
"      Rich MM, Bird SJ, Raps EC, et al. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997; 20:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/23\">",
"      Allen DC, Arunachalam R, Mills KR. Critical illness myopathy: further evidence from muscle-fiber excitability studies of an acquired channelopathy. Muscle Nerve 2008; 37:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/24\">",
"      Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve 2000; 23:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/25\">",
"      Trojaborg W. Electrophysiologic techniques in critical illness-associated weakness. J Neurol Sci 2006; 242:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/26\">",
"      Rouleau G, Karpati G, Carpenter S, et al. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve 1987; 10:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/27\">",
"      Di Giovanni S, Mirabella M, D'Amico A, et al. Apoptotic features accompany acute quadriplegic myopathy. Neurology 2000; 55:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/28\">",
"      Di Giovanni S, Molon A, Broccolini A, et al. Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 2004; 55:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/29\">",
"      Capasso M, Di Muzio A, Pandolfi A, et al. Possible role for nitric oxide dysregulation in critical illness myopathy. Muscle Nerve 2008; 37:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/30\">",
"      Rich MM, Pinter MJ, Kraner SD, Barchi RL. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998; 43:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/31\">",
"      Mozaffar T, Haddad F, Zeng M, et al. Molecular and cellular defects of skeletal muscle in an animal model of acute quadriplegic myopathy. Muscle Nerve 2007; 35:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/32\">",
"      Rossignol B, Gueret G, Pennec JP, et al. Effects of chronic sepsis on the voltage-gated sodium channel in isolated rat muscle fibers. Crit Care Med 2007; 35:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/33\">",
"      Latronico N, Shehu I, Seghelini E. Neuromuscular sequelae of critical illness. Curr Opin Crit Care 2005; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     Lacomis, D. Management of generalized weakness in medical and surgical intensive care units. In: Neurological Therapeutics, Principles and Practice, Noseworthy, J (Ed), Martin Dunitz Ltd 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/35\">",
"      Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005; 64:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/36\">",
"      Hermans G, Wilmer A, Meersseman W, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 2007; 175:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/37\">",
"      Zochodne DW, Bolton CF, Wells GA, et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain 1987; 110 ( Pt 4):819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/38\">",
"      Witt NJ, Zochodne DW, Bolton CF, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/39\">",
"      Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984; 47:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/40\">",
"      Roelofs, R, Cerra, F, Bilka, N, et al. Prolonged respiratory insufficiency due to acute motor neuropathy: A new syndrome?. Neurology 1983; 33:s240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/41\">",
"      Sander HW, Golden M, Danon MJ. Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve 2002; 26:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/42\">",
"      Garnacho-Montero J, Amaya-Villar R, Garc&iacute;a-Garmend&iacute;a JL, et al. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 2005; 33:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/43\">",
"      Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Curr Opin Crit Care 2005; 11:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/44\">",
"      Bolton, C. The polyneuropathy of critical illness. Intensive Care Med 1994; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/45\">",
"      Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/46\">",
"      Op de Coul AA, Verheul GA, Leyten AC, et al. Critical illness polyneuromyopathy after artificial respiration. Clin Neurol Neurosurg 1991; 93:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/47\">",
"      Bednarik J, Lukas Z, Vondracek P. Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Intensive Care Med 2003; 29:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/48\">",
"      Khan J, Harrison TB, Rich MM, Moss M. Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology 2006; 67:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/49\">",
"      Novak KR, Nardelli P, Cope TC, et al. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest 2009; 119:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/50\">",
"      Latronico N, Bertolini G, Guarneri B, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care 2007; 11:R11.",
"     </a>",
"    </li>",
"    <li>",
"     Latronico, N. Axonal inexcitability and axonal degeneration: two sides of the same coin [ELetter]. J Clin Invest 2009; April 27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/52\">",
"      Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995; 332:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/53\">",
"      Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/54\">",
"      Deem S, Lee CM, Curtis JR. Acquired neuromuscular disorders in the intensive care unit. Am J Respir Crit Care Med 2003; 168:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43976/abstract/55\">",
"      Agoston S, Vandenbrom RH, Wierda JM. Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 1992; 22:94.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5144 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43976=[""].join("\n");
var outline_f42_60_43976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cachectic myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CRITICAL ILLNESS MYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical features of CIM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory and electrodiagnostic findings in CIM",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Direct muscle stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathology and pathogenesis of CIM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnosis of CIM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment and prognosis of CIM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CRITICAL ILLNESS POLYNEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Association with sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical features of CIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory and electrodiagnostic findings in CIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnosis of CIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment and prognosis of CIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMBINED CRITICAL ILLNESS MYOPATHY AND POLYNEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROLONGED NEUROMUSCULAR JUNCTION BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5144|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/3/38971\" title=\"table 1\">",
"      Criteria CIM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/49/33563\" title=\"table 2\">",
"      Criteria CIP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43977="Overview of hemolytic anemias in children";
var content_f42_60_43977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hemolytic anemias in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43977/contributors\">",
"     Michael Recht, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43977/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/60/43977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/60/43977/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/60/43977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is among the most frequent laboratory abnormalities seen by a practicing pediatrician. Approximately 20 percent of all children in the United States and 80 percent of children in developing countries will be anemic at some time before their 18th birthdays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/1\">",
"     1",
"    </a>",
"    ]. Anemia is caused by one of three broad mechanisms: decreased production of red blood cells, increased loss of red blood cells, or destruction of red blood cells. Worldwide, the vast majority of childhood anemias are due to iron deficiency, due to either inadequate dietary intake or blood loss associated with gastrointestinal infections such as hookworm. However, the hemolytic anemias are associated with excessive morbidity and mortality.",
"   </p>",
"   <p>",
"    The approach to a child with hemolytic anemia is discussed here. An overall approach to the anemic child, including the characteristics that suggest a hemolytic process, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THE HEMOLYTIC PROCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After release from the bone marrow, mature, nonnucleated erythrocytes (red blood cells, RBCs) survive for 100 to 120 days in the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/2\">",
"     2",
"    </a>",
"    ]. In the steady state, approximately 1 percent of the circulating erythrocytes are destroyed daily (ie, senescent RBCs) and are replaced by an equal number of new erythrocytes released from the bone marrow (ie, reticulocytes) (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74294 \" href=\"mobipreview.htm?35/61/36822\">",
"     picture 2",
"    </a>",
"    ). The basic pathophysiology of the hemolytic anemias is a reduced erythrocyte lifespan, ranging from nearly normal to remarkably shortened. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In compensation for a reduced RBC lifespan, the bone marrow increases its output of erythrocytes, a response mediated by increased production of erythropoietin. As an example, in adults with hereditary spherocytosis, the bone marrow can increase its output of erythrocytes six- to eight-fold. With this maximal response, erythrocyte survival can be reduced to a value as low as 20 to 30 days without the onset of anemia (ie, fully compensated hemolysis). The limits of erythrocyte production in other hemolytic states have not been determined, particularly in infants and children, but they probably are lower in infants than in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of increased RBC production in response to hemolysis, the reticulocyte count often exceeds 2 percent, with an absolute reticulocyte count usually greater than",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/3\">",
"     3",
"    </a>",
"    ]. When a chronic hemolytic process is present, hyperplasia of the erythropoietic marrow elements occurs, with reversal of the myeloid-to-erythroid ratio from the normal 3:1 to 1:1 or less (",
"    <a class=\"graphic graphic_picture graphicRef51478 \" href=\"mobipreview.htm?39/42/40611\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75057 \" href=\"mobipreview.htm?42/36/43589\">",
"     picture 4",
"    </a>",
"    ). In the severe, chronic hemolytic processes of childhood (eg, thalassemia major, congenital spherocytosis, sickle cell disease), hypertrophy of the marrow may expand the medullary spaces, producing bony changes, particularly in the skull and hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Reticulocyte count'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Skeletal changes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Bone complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hemolytic process can be measured directly by determining erythrocyte survival or indirectly via the presence of increased levels of the metabolic products of hemolysis (eg, increased indirect bilirubin, increased lactate dehydrogenase, reduced haptoglobin). Alternatively, a hemolytic process may be inferred, in a non-bleeding patient, by documentation of the increase in the erythrocyte production (eg, presence of reticulocytosis) that usually accompanies hemolytic states. However, reticulocytosis may also be seen in some non-hemolytic conditions such as the recovery phase after an aplastic event (eg, after transient erythroblastopenia of childhood, TEC) or child with anemia caused by iron or vitamin B12 deficiency, who is responding to treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link&amp;anchor=H6#H6\">",
"     \"Red blood cell survival: Normal values and measurement\", section on 'Estimation of red cell survival from the reticulocyte count'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Elevations of unconjugated bilirubin often occur in children with hemolytic anemias. However, overt clinical jaundice may be absent or may be missed. In addition, total bilirubin levels in excess of 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    are unusual if hepatic function is normal. The increased excretion of bilirubin pigments that occurs in patients with chronic hemolysis also may lead to the production of pigmented gallstones that may develop in early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43880?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the child with anemia\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\", section on 'Gallstones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In any hemolytic state, hemoglobin is released into the plasma, where it combines irreversibly with serum haptoglobin. The large hemoglobin-haptoglobin complex is then rapidly cleared from the circulation by the liver. Because the synthetic and binding capacities of haptoglobin are limited, serum levels of haptoglobin in hemolysis usually are either decreased (&lt;20",
"    <span class=\"nowrap\">",
"     mg/dl)",
"    </span>",
"    or absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/6\">",
"     6",
"    </a>",
"    ]. Low or absent haptoglobin is not necessarily a reliable indicator of acute hemolysis, since congenital haptoglobin deficiency can be as high as 30 percent in some West African populations. Furthermore, haptoglobin is not measureable before two to three months of age.",
"   </p>",
"   <p>",
"    Besides these indirect indicators of hemolysis, isotopic or non-isotopic techniques can measure erythrocyte survival directly. Radioactive sodium chromate (51Cr) most often is used as an erythrocyte tag in adults, whereas non-radioactive techniques using",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    are available for use in neonates and children. A shortened erythrocyte survival is likely when the 51Cr RBC half-life is reduced below 20 days (normal: 28 to 37 days). However, employing such survival studies in clinical practice is not necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link&amp;anchor=H7#H7\">",
"     \"Red blood cell survival: Normal values and measurement\", section on 'Random label red blood cell survival method'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemolytic disorders may be classified according to whether the shortened erythrocyte survival is a result of an intrinsic abnormality of the erythrocyte, or an extrinsic abnormality acting on a normal erythrocyte (",
"    <a class=\"graphic graphic_table graphicRef64454 \" href=\"mobipreview.htm?0/31/508\">",
"     table 1",
"    </a>",
"    ). These two categories are not mutually exclusive because some hemolytic disorders are caused by a combination of intrinsic and extrinsic mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intrinsic",
"      </strong>",
"      hemolytic anemias generally result from inherited abnormalities of hemoglobin, the erythrocyte membrane, or intracellular red cell enzymes. These include conditions such as sickle cell disease and thalassemia (which are discussed in detail in separate topic reviews), hereditary spherocytosis, elliptocytosis and stomatocytosis, paroxysmal nocturnal hemoglobinuria, and pyruvate kinase and glucose-6-phosphate dehydrogenase deficiencies.",
"     </li>",
"     <li>",
"      <strong>",
"       Extrinsic",
"      </strong>",
"      disorders usually are acquired and result from forces or agents that immunologically, chemically, or physically damage the erythrocyte. These include autoimmune hemolytic anemias, hypersplenism (eg, from portal hypertension), and certain oxidant agents such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/31/34288?source=see_link\">",
"       dapsone",
"      </a>",
"      and nitrites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INTRINSIC HEMOLYTIC ANEMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25094836\">",
"    <span class=\"h2\">",
"     Hemoglobinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following hemoglobinopathies are common causes of hemolytic disease, and are discussed in detail in separate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The thalassemias (primarily beta thalassemia major and hemoglobin H disease) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sickle cell disease (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"       \"Overview of the clinical manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unstable hemoglobins such as congenital Heinz body hemolytic anemias, hemoglobin Hasharon, and hemoglobin Poole. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/616?source=see_link\">",
"       \"Unstable hemoglobin variants\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hereditary spherocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spherocytosis (HS) occurs predominantly in persons of North European ancestry, although it has been found in patients of many ethnic groups. The typical features are a familial hemolytic anemia of various degrees of severity, splenomegaly, and spherical erythrocytes found on the blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"mobipreview.htm?27/1/27670\">",
"     picture 5",
"    </a>",
"    ). In approximately three-quarters of patients, pedigree analysis indicates an autosomal dominant transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/7\">",
"     7",
"    </a>",
"    ]. Sporadic dominant mutations have been invoked, and autosomal recessive transmission is suggested in some cases. The gene for HS is located in chromosome 8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathophysiology &mdash; A deficiency or abnormality of the erythrocyte membrane structural protein spectrin appears to affect most patients with HS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/9\">",
"     9",
"    </a>",
"    ]. Other erythrocyte membrane structural proteins that have been demonstrated to play a role in this disease include ankyrin, band 3, and protein 4.2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/10\">",
"     10",
"    </a>",
"    ]. They all have in common a relative deficiency of spectrin. This deficiency is associated with an accelerated loss of the erythrocyte membrane, which reduces the erythrocyte surface area. Because there is no concomitant loss of cellular volume, the erythrocytes assume a spherical shape. Increased membrane cation flux also can be demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spleen is intrinsically involved in the hemolytic process because the splenic circulation imposes a metabolic stress on spherocytic cells. The spherocyte is relatively rigid and non-deformable and passes with difficulty through the splenic cords and sinuses. This results in their sequestration and destruction. The hemolytic process regresses after splenectomy, but biochemical and morphologic abnormalities persist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H28#H28\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Extravascular nonimmune hemolysis due to hypersplenism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical presentation &mdash; Hereditary spherocytosis may present in the neonatal period with anemia and hyperbilirubinemia that may require phototherapy or exchange transfusion. Alternatively, it may present during childhood or adulthood with splenomegaly or chronic anemia. The degree of anemia varies considerably in severity but tends to be similar within the same family. The patient usually has slight jaundice, and the spleen almost always is palpably enlarged after two or three years of age. Expansion of the marrow cavities occurs to a lesser extent than in thalassemia. Some patients are first diagnosed when they experience an acute exacerbation of the anemia due to an aplastic, hemolytic, or megaloblastic crisis. Aplastic crises associated with parvovirus infections are the most serious complications during childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\", section on 'Transient aplastic crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory findings &mdash; Indicators of hemolysis include reticulocytosis, anemia, and hyperbilirubinemia. The hemoglobin level ranges from 6 to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and the reticulocyte count from 5 to 20 percent (average 10 percent). The spherocytic erythrocytes are smaller than normal erythrocytes and lack the central pallor of the biconcave disk, but only a relatively small proportion of the cells are spherocytic (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"mobipreview.htm?27/1/27670\">",
"     picture 5",
"    </a>",
"    ). Erythroid hyperplasia is present in the marrow (",
"    <a class=\"graphic graphic_picture graphicRef75057 \" href=\"mobipreview.htm?42/36/43589\">",
"     picture 4",
"    </a>",
"    ), but erythrocyte precursors are not spherocytic.",
"   </p>",
"   <p>",
"    Abnormality of the erythrocyte can be demonstrated by osmotic fragility studies. When erythrocytes are placed in hypotonic saline solutions, water enters the cells, causing them to swell. The normal biconcave erythrocyte can increase its volume, but the spherical cell already has maximal volume for its surface area and hemolyzes at a higher saline concentration (ie, increased osmotic fragility) than normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/13\">",
"     13",
"    </a>",
"    ]. In 10 to 20 percent of HS cases, the osmotic abnormality can be demonstrated only if the blood is first incubated at 37&ordm;C for 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=see_link&amp;anchor=H8#H8\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Specific diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HS must be differentiated from other congenital hemolytic states. Family history, blood smear, and osmotic fragility studies offer the most diagnostic value. Acquired spherocytosis of the erythrocytes is seen in autoimmune hemolytic anemias, in which the spherocytosis is often more pronounced than in HS, and the direct antiglobulin test is positive. In a newborn infant, differentiating HS from hemolytic disease secondary to ABO incompatibility may be difficult. A period of observation may be necessary to clarify the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Acquired spherocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy &mdash; Splenectomy almost invariably produces a clinical cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/15\">",
"     15",
"    </a>",
"    ] except in a few instances of severe HS with recessive transmission. Splenectomy should be deferred if possible until the patient is at least five or six years of age because splenic function is important in younger children to protect them from sepsis caused by encapsulated bacteria such as pneumococcus. Supportive care prior to splenectomy includes blood transfusions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythropoietin during infancy and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation. If anemia is severe enough to impair growth or normal activity, the operation can be considered earlier. Splenectomy prevents gallstones and eliminates the threat of aplastic crisis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=see_link&amp;anchor=H9#H9\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After splenectomy, jaundice and reticulocytosis disappear. The hemoglobin concentration becomes normal, although the spherocytosis and osmotic fragility abnormalities become more pronounced. Overwhelming sepsis after splenectomy occurs less frequently if the surgery is delayed until the child is five or six years of age, but the febrile asplenic child must always be carefully and urgently evaluated for sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunization with polyvalent pneumococcal vaccine should be complete at least two weeks before splenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/17\">",
"     17",
"    </a>",
"    ]. Prophylactic penicillin therapy after splenectomy is advocated by some authorities, and it definitely is indicated if the operation is performed before the child is six years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Pneumococcal vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hereditary elliptocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary elliptocytosis (HE) is a dominantly inherited trait characterized by large numbers of oval or elliptical erythrocytes (",
"    <a class=\"graphic graphic_picture graphicRef63129 \" href=\"mobipreview.htm?9/61/10199\">",
"     picture 6",
"    </a>",
"    ); lower frequencies of oval or elliptical erythrocytes may be seen in numerous conditions, especially thalassemia and iron deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/19\">",
"     19",
"    </a>",
"    ]. In most patients, no associated hemolysis occurs and the hematologic values, including reticulocyte counts, are normal. However, in approximately 10 percent of patients with elliptical cells, evidence of hemolysis exists, with hemoglobin levels averaging 8 to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and reticulocytes comprising 5 to 15 percent of the circulating red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathophysiology &mdash; A structural abnormality of spectrin has been described in erythrocytes from some patients with HE with or without hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/21\">",
"     21",
"    </a>",
"    ]. The basis for hemolytic HE and HE without hemolysis are unclear. In most family studies of hemolytic HE, one parent has elliptical erythrocytes without hemolysis and the other parent is hematologically normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/56/43911?source=see_link\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical presentation &mdash; HE with hemolysis may be associated with neonatal jaundice, but characteristic elliptocytosis may not be evident at birth. The blood smear instead shows bizarre poikilocytes and pyknocytes, the latter being described as small, distorted, irregular, densely stained red cells with spiny projections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/22\">",
"     22",
"    </a>",
"    ]. This condition has been called infantile pyknocytosis. The usual features of a chronic hemolytic process, including anemia, jaundice, splenomegaly, and osseous changes, may be seen later. Cholelithiasis occurs in later childhood. Aplastic crises have been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=see_link\">",
"     \"Hereditary elliptocytosis: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14583?source=see_link&amp;anchor=H11#H11\">",
"     \"Xerocytosis\", section on 'Infantile pyknocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory findings &mdash; The morphology of the erythrocytes is the most important diagnostic feature of HE. Elliptical cells, characterized by a length more than 1.5 times the diameter, account for 15 percent to 70 percent of the erythrocytes (",
"    <a class=\"graphic graphic_picture graphicRef63129 \" href=\"mobipreview.htm?9/61/10199\">",
"     picture 6",
"    </a>",
"    ). In hemolytic HE, the reticulocyte count is increased. Erythroid hyperplasia is evident in the bone marrow, but the erythrocyte precursors are not elliptical. Increased erythrocyte osmotic fragility and increased thermal instability occur in hemolytic HE, which has sometimes led to designating cases of hemolytic HE as pyropoikilocytosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary elliptocytosis: Clinical features and diagnosis\", section on 'Hereditary pyropoikilocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy &mdash; If significant hemolysis exists, splenectomy usually is beneficial. Erythrocyte morphology is not changed after the operation, and it may become even more abnormal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=see_link&amp;anchor=H9#H9\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hereditary stomatocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary stomatocytosis is a rare hemolytic anemia associated with erythrocytes that are swollen and cup-shaped. On stained smears, they have a mouth-like slit (ie, stoma) in place of the usual circular central pallor (",
"    <a class=\"graphic graphic_picture graphicRef75535 \" href=\"mobipreview.htm?8/51/9015\">",
"     picture 7",
"    </a>",
"    ). Hemolytic anemia is associated with extreme permeability of the erythrocyte membrane to cations. Splenectomy may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42200?source=see_link\">",
"     \"Stomatocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Abnormalities of erythrocyte glycolytic enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemias caused by inherited abnormalities of erythrocyte glycolytic enzymes include pyruvate kinase deficiency, glucose-6-phosphate dehydrogenase (G6PD) deficiency, deficiencies of hexokinase, glucose-6 phosphate isomerase, phosphofructokinase, aldolase, triosephosphate isomerase, glyceraldehyde-3-phosphate isomerase, and phosphoglycerate kinase. Most are inherited as autosomal recessive disorders. Most of these conditions are mild and uncommon, with the exception of glucose-6-phosphate dehydrogenase (G6PD) deficiency. These disorders are reviewed briefly here, and more detail is provided in linked topic reviews.",
"   </p>",
"   <p>",
"    This group of congenital hemolytic anemias originally was classified as &ldquo;nonspherocytic&rdquo; because spherocytic erythrocytes were not found and results of the osmotic fragility tests were normal. A diagnosis is established by demonstrating reduction of the enzyme as well as decreased levels of glycolytic metabolites distal to the deficient enzyme. Deficiencies of glycolytic enzymes compromise adenosine triphosphate generation. The metabolic energy requirements of the erythrocytes cannot be met, and the erythrocyte lifespan is shortened.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pyruvate kinase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inherited deficiency of pyruvate kinase (PK) is the most common of the erythrocyte glycolytic enzyme deficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/23\">",
"     23",
"    </a>",
"    ]. PK activity, measured in the erythrocytes, is reduced markedly, but the enzyme activity in other blood cells and tissues is normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27559?source=see_link\">",
"     \"Pyruvate kinase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pathophysiology &mdash; The disease is caused by homozygosity for a mutant PK gene, resulting in markedly decreased activity of an abnormal PK isoenzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/24\">",
"     24",
"    </a>",
"    ]. The PK-deficient erythrocytes are depleted of adenosine triphosphate (ATP), and their survival is compromised. Levels of glycolytic intermediates, especially 2,3-diphosphoglycerate (2,3-DPG, also called 2,3 bisphosphoglycerate), are increased greatly. The increase in 2,3-DPG causes a rightward shift of the oxygen dissociation curve that may reduce symptoms of the accompanying anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link&amp;anchor=H9#H9\">",
"     \"Structure and function of normal human hemoglobins\", section on '2,3-bisphosphoglycerate'",
"    </a>",
"    .) Heterozygotes for PK deficiency have intermediate enzyme levels and are not clinically affected.",
"   </p>",
"   <p>",
"    Clinical presentation &mdash; In PK-deficient homozygotes, a broad spectrum of clinical and hematologic findings occurs, ranging from a mild, completely compensated hemolytic state to severe anemia. Anemia and hyperbilirubinemia may occur in the neonatal period. In the older patient, pallor, scleral icterus, and splenomegaly are usual findings.",
"   </p>",
"   <p>",
"    Laboratory findings &mdash; The blood smear shows polychromatophilic erythrocytes (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 1",
"    </a>",
"    ), indicating an elevated reticulocyte count. A few small spiculated erythrocytes are seen, but no increased number of spherocytes is found. Osmotic fragility is normal.",
"   </p>",
"   <p>",
"    Treatment &mdash; Hyperbilirubinemia in the neonatal period may require exchange transfusion. Severe disease may require repeated transfusions for anemia during infancy. Splenectomy, although not curative, may improve the anemia and should be considered in patients with severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/25\">",
"     25",
"    </a>",
"    ]. Marked reticulocytosis occurs after splenectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Glucose-6-phosphate dehydrogenase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase (G6PD) deficiency results in two kinds of hematologic problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A common condition manifested by",
"      <strong>",
"       acute",
"      </strong>",
"      hemolytic episodes induced by infection or certain drugs (",
"      <a class=\"graphic graphic_table graphicRef74254 \" href=\"mobipreview.htm?19/22/19821\">",
"       table 2",
"      </a>",
"      ). This pattern is characteristic of patients with Class II and III variants.",
"     </li>",
"     <li>",
"      A rare, chronic, nonspherocytic hemolytic anemia. This type is known as a Class I variant, characterized by severe deficiency of G6PD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The G6PD gene is found on the X chromosome. In the affected hemizygous male subject, the condition results from inheritance of one abnormal G6PD gene. In the affected homozygous female subject, two abnormal genes are inherited. The normal G6PD enzyme found in most white populations is designated G6PD B+, whereas a normal isoenzyme designated G6PD A+ is common in blacks. More than 10 distinct enzyme variants of G6PD have been documented. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=see_link&amp;anchor=H4#H4\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\", section on 'G6PD and its variants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pathophysiology &mdash; A mutant enzyme called G6PD A- is found in approximately 13 percent of black men and 2 percent of black women. This enzyme is unstable and is associated with reduced erythrocyte enzyme activity (5 to 15 percent of normal) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/26\">",
"     26",
"    </a>",
"    ]. Affected persons of Mediterranean, Arabic, and Asian ethnic groups have relatively high frequencies of G6PD deficiency because of a variant designated as G6PD B- [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/27\">",
"     27",
"    </a>",
"    ]. In the Mediterranean variant, the enzyme activity of the homozygous female or the hemizygous male subject is less than 5 percent of normal.",
"   </p>",
"   <p>",
"    G6PD, the rate-limiting enzyme of the pentose phosphate pathway, is crucial for protection of the erythrocytes from oxidant stress. In G6PD deficiency, oxidant metabolites of numerous drugs result in denaturation and precipitation of hemoglobin, causing erythrocyte injury and rapid hemolysis. However, the acute hemolysis occurs only if the patient is exposed to oxidant drugs, such as naphthalene, sulfonamides, antimalarials, and naphthoquinones, or to the fava bean (",
"    <a class=\"graphic graphic_table graphicRef74254 \" href=\"mobipreview.htm?19/22/19821\">",
"     table 2",
"    </a>",
"    ). The degree of hemolysis varies with the drug's antioxidant effect, the amount ingested, and the severity of the enzyme deficiency in the patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory findings &mdash; Hemoglobinemia and hemoglobinuria occur 24 to 48 hours after the ingestion of an oxidant substance. The hemoglobin level may decrease acutely to as low as 2 to 5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    \"Bite cells\" and Heinz bodies (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"mobipreview.htm?25/28/26054\">",
"     picture 8",
"    </a>",
"    ) are observed during this time. Heinz bodies are not visible on stained blood smears, but they can be demonstrated on supravitally-stained preparations. Both disappear after three or four days. Spontaneous recovery is usual and is heralded by reticulocytosis and an increase in hemoglobin concentration, starting four or five days after the acute hemolytic episode.",
"   </p>",
"   <p>",
"    Diagnosis depends on direct or indirect demonstration of reduced G6PD activity in erythrocytes. By direct measurement, enzyme activity in affected persons is less than 15 percent of normal. The reduction of enzyme activity is more extreme in whites and Asians than in G6PD-deficient blacks. Shortly after a hemolytic event, and at a time when a reticulocyte response has occurred, G6PD activity may be normal, secondary to the fact that G6PD activity is higher in reticulocytes. A repeat examination several weeks later, when the reticulocytosis has abated, may be necessary in order to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy &mdash; Prevention of hemolysis by avoiding oxidant drugs is of paramount importance. Men and boys belonging to ethnic groups in which a significant incidence of G6PD deficiency occurs should be tested for the defect before drugs that are known to be potent oxidants are given. After hemolysis has occurred, supportive therapy, including blood transfusions if the anemia is severe and the patient symptomatic, is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Other glycolytic enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiencies of several other glycolytic erythrocyte enzymes have been described in patients with congenital nonspherocytic hemolytic anemia. They include deficiencies of hexokinase, glucose-6 phosphate isomerase, phosphofructokinase, aldolase, triosephosphate isomerase, glyceraldehyde-3-phosphate isomerase, and phosphoglycerate kinase.",
"   </p>",
"   <p>",
"    These diseases are extremely rare and most are transmitted as autosomal recessive traits. Some of them, as listed below, are associated with neurologic disease, metabolic myopathy, and abnormal glycogen metabolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/905?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the metabolic myopathies\", section on 'Disorders of glycogen metabolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphofructokinase deficiency &mdash; a metabolic myopathy with hemolytic anemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28596?source=see_link\">",
"       \"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phosphoglycerate kinase deficiency &mdash; central nervous system dysfunction with seizures and intellectual disability (mental retardation) associated with nonspherocytic hemolytic anemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44341?source=see_link&amp;anchor=H2#H2\">",
"       \"Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency\", section on 'Phosphoglycerate kinase deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aldolase deficiency (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40500?source=see_link\">",
"       \"Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Triosephosphate isomerase deficiency &mdash; hemolytic anaemia coupled with a progressive, severe neurologic disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic hemolysis, often manifested in infancy, is a common feature. Specific erythrocyte morphologic abnormalities are not seen. Diagnosis depends on demonstration of reduction of the specific erythrocyte enzyme. No specific therapy exists; splenectomy may reduce the rate of hemolysis in some, but not all, of these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other pentose phosphate pathway enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important function of the pentose pathway is to provide the NADPH (reduced nicotinamide-adenine dinucleotide phosphate) necessary for maintaining glutathione in the reduced state, essential for the physiologic inactivation of oxidant compounds. Without adequate levels of glutathione, when oxidant drugs are ingested, hemoglobin becomes denatured and precipitates into erythrocyte inclusions called Heinz bodies (",
"    <a class=\"graphic graphic_picture graphicRef73790 \" href=\"mobipreview.htm?25/28/26054\">",
"     picture 8",
"    </a>",
"    ). These bodies damage the erythrocyte membrane, resulting in acute hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     EXTRINSIC HEMOLYTIC ANEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemias caused by agents that damage normal erythrocytes and lead to their premature destruction are categorized as &ldquo;extrinsic&rdquo; (",
"    <a class=\"graphic graphic_table graphicRef64454 \" href=\"mobipreview.htm?0/31/508\">",
"     table 1",
"    </a>",
"    ). These include the autoimmune hemolytic anemias (warm- and cold-reacting), hypersplenism, microangiopathies including hemolytic-uremic syndrome (HUS) and disseminated intravascular coagulation (DIC), paroxysmal cold hemoglobinuria (PCH), and paroxysmal nocturnal hemoglobinuria (PNH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2936114\">",
"    <span class=\"h2\">",
"     Autoimmune hemolytic anemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most clearly defined of these agents are antibodies directed against specific intrinsic membrane antigens that damage the erythrocyte and produce hemolysis, causing an autoimmune hemolytic anemia (AIHA). These disorders are identified by positive results to the direct antiglobulin test (also known as the Coombs' test), which detects immunoglobulins (eg, IgG or IgM) or components of complement on the erythrocyte surface. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/59/18362?source=see_link\">",
"     \"Autoimmune hemolytic anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In primary AIHA, red blood cell autoantibodies are present and cause hemolytic anemia, but no evidence of an underlying systemic illness exists. Primary AIHA can be subclassified according to the characteristics of the erythrocyte autoantibodies and autoantigens, into warm-reactive AIHA, cold agglutinin disease, or paroxysmal cold hemoglobinuria (",
"    <a class=\"graphic graphic_table graphicRef55710 \" href=\"mobipreview.htm?12/53/13148\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Secondary AIHA is an immune-mediated hemolytic anemia which occurs in the setting of a broader systemic disorder, such as systemic lupus erythematosus or another autoimmune disorder, malignancy, immunodeficiency, or following certain infections (",
"    <a class=\"graphic graphic_table graphicRef57399 \" href=\"mobipreview.htm?16/26/16811\">",
"     table 4",
"    </a>",
"    ). Drugs such as penicillin, cephalosporins, and alpha-methyldopa evoke the formation of antibodies in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/59/18362?source=see_link\">",
"     \"Autoimmune hemolytic anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Warm-reactive hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In warm-reactive AIHA (warm-agglutinin disease), circulating antibodies are directed against the patient's own erythrocytes. The factor(s) evoking such an autoimmune response are unknown but include viral infections and occasionally specific drugs.",
"   </p>",
"   <p>",
"    Clinical manifestations &mdash; Warm-agglutinin disease tends to occur in two clinical patterns (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A fulminant disease course is typical for primary AIHA. The onset is acute, with pallor, jaundice, and hemoglobinuria, often preceded by a respiratory infection. The spleen is enlarged. A consistent response to corticosteroid therapy, low mortality, and complete recovery are characteristic. No underlying disease is found [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A more chronic disease course is more typical for secondary AIHA (eg, that associated with an underlying disease such as lymphoma or systemic lupus erythematosus). This pattern of AIHA has a prolonged course and a significant mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory findings &mdash; The anemia may be severe, with hemoglobin levels of less than 6",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Spherocytosis and polychromasia are prominent. Reticulocytosis and nucleated erythrocytes are found, and leukocytosis is common. The platelet count usually is normal; occasionally, there is an associated immune thrombocytopenia (ITP, previously known as idiopathic thrombocytopenic purpura). The combination of autoimmune hemolytic anemia and immune thrombocytopenia is known as Evans syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/59/18362?source=see_link&amp;anchor=H28#H28\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Evans syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The result of the direct Coombs test is positive, indicating the presence of antibodies attached to the erythrocytes or free in the serum, respectively. These antibodies belong to the IgG class. They often are nonspecific panagglutinins, but they may have specificity for ubiquitous antigens of the Rh system (eg, E, LW). Because of spontaneous erythrocyte agglutination, the patient may be mistakenly typed as blood group AB, Rh+ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/31\">",
"     31",
"    </a>",
"    ]. In acute, transient cases, only complement is found on the erythrocytes, chiefly the C3 and C4 components. In chronic AIHA, a pure IgG Coombs' tests result is often found. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Direct Coombs' test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment &mdash; Transfusion may be required, but offers only transient benefit. Completely compatible blood is difficult to find, and giving blood that is \"incompatible\" as judged by the cross-match often is necessary.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     Prednisone",
"    </a>",
"    should be administered in a dose of 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PO every 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/32\">",
"     32",
"    </a>",
"    ]. Treatment should continue until hemolysis decreases. The dose can then be gradually reduced.",
"   </p>",
"   <p>",
"    The acute form of the disease usually remits spontaneously within a few weeks or months, but the Coombs test may remain positive for an extended period. Splenectomy and immunosuppressive agents may be beneficial in patients refractory to conventional therapy. In AIHA secondary to lymphoma or lupus erythematosus, the disease tends to be chronic and the course of the underlying disease determines the ultimate prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Cold-agglutinin hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of cold antibodies may exist normally, but they may increase to very high levels after some viral or mycoplasmal infections. These high titers of cold antibodies induce intravascular hemolysis with resulting hemoglobinemia and hemoglobinuria. Because the hemolysis is primarily intravascular, dark-colored urine is more common and splenomegaly is less common than in warm-reactive disease.",
"   </p>",
"   <p>",
"    The antibodies often have specificity for the I antigen and react poorly with human cord blood cells possessing the I antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/33\">",
"     33",
"    </a>",
"    ]. The antibodies are of the IgM class and require complement for activity. Spontaneous agglutination and rouleaux formation are seen on the blood smear (",
"    <a class=\"graphic graphic_picture graphicRef50522 \" href=\"mobipreview.htm?15/10/15527\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30535?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=see_link\">",
"     \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with infectious mononucleosis may develop acute hemolytic anemia. The antibodies in these cases have anti-I specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=see_link&amp;anchor=H15#H15\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Hematologic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Paroxysmal cold hemoglobinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal cold hemoglobinuria (PCH) is a rare condition associated with a specific type of cold antibody, the Donath-Landsteiner hemolysin, which has anti-P specificity. Intravascular hemolysis is precipitated by low environmental temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/35\">",
"     35",
"    </a>",
"    ]. Approximately one-third of cases in the past were associated with congenital or acquired syphilis. PCH now is seen in two clinical situations: in children following viral infection and in adults as an autoimmune disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16422?source=see_link\">",
"     \"Paroxysmal cold hemoglobinuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2935927\">",
"    <span class=\"h2\">",
"     Paroxysmal nocturnal hemoglobinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal nocturnal hemoglobinuria (PNH) is a rare chronic anemia with prominent intravascular hemolysis that may have its onset in late childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/36\">",
"     36",
"    </a>",
"    ]. Hemolysis is characteristically worse during sleep, and morning hemoglobinuria usually is present.",
"   </p>",
"   <p>",
"    The primary defect in PNH resides in an abnormal surface protein anchor to the red blood cell membrane. This extracellular anchor, or glycosylphosphatidyl-inositol (GPI), is missing from all cells in those patients affected with PNH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/37\">",
"     37",
"    </a>",
"    ]. PNH is a clonal abnormality, with the PIG-A gene mutated in affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/38\">",
"     38",
"    </a>",
"    ]. This abnormality renders erythrocytes susceptible to hemolysis by serum complement. The hemoglobinuria is explainable because red blood cells no longer express CD55 and CD59, both of which are required for clearance of randomly deposited complement factors from the erythrocyte membrane, which allows chronic complement-mediated intravascular hemolysis. Infections tend to trigger episodes of hemolysis, although frequently no identifiable reason exists. In addition to chronic hemolysis, thrombocytopenia and leukopenia may develop. Some cases have been followed by aplastic anemia, myelodysplasia, or acute leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42392?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13593?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13593?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\", section on 'Importance of CD59'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=see_link\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously, the diagnosis was suggested by a positive result in the acidified serum (Ham test) or thrombin or sucrose lysis tests. Currently, the diagnosis is established by demonstrating the absence of CD55 or CD59 on the surface of erythrocytes. Therapy is supportive and symptomatic, although oral corticosteroids at a dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    have shown effectiveness at limiting the duration of the hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/39\">",
"     39",
"    </a>",
"    ]. Hematopoietic cell transplantation has been successful in some cases in both adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/60/43977/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    is emerging as a promising therapy in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17082?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17082?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Eculizumab'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2998504\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The basic pathophysiology of the hemolytic anemias is a reduced erythrocyte lifespan. In compensation for a reduced RBC lifespan, the bone marrow increases its output of erythrocytes. In the severe, chronic hemolytic processes of childhood, hypertrophy of the marrow may expand the medullary spaces, producing bony changes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of the hemolytic process'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A hemolytic process can be measured directly by determining erythrocyte survival or indirectly via the presence of increased levels of the metabolic products of hemolysis (eg, reduced haptoglobin, or increased indirect bilirubin or lactate dehydrogenase). Alternatively, a hemolytic process may be inferred, from signs of an increase in the erythrocyte production (eg, presence of reticulocytosis). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hemolytic disorders may be classified according to whether the shortened erythrocyte survival is a result of an intrinsic abnormality of the erythrocyte or an extrinsic abnormality acting on a normal erythrocyte (",
"      <a class=\"graphic graphic_table graphicRef64454 \" href=\"mobipreview.htm?0/31/508\">",
"       table 1",
"      </a>",
"      ). These two categories are not mutually exclusive. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary spherocytosis (HS) is a familial hemolytic anemia of variable severity, with splenomegaly, and spherical erythrocytes found on the blood smear (",
"      <a class=\"graphic graphic_picture graphicRef70611 \" href=\"mobipreview.htm?27/1/27670\">",
"       picture 5",
"      </a>",
"      ). Patients may present in the neonatal period with hyperbilirubinemia or during childhood or adulthood with splenomegaly or chronic anemia. Patients are at risk for acute exacerbations of the anemia due to an aplastic, hemolytic, or megaloblastic crisis. Splenectomy almost invariably produces a clinical cure but should be deferred until age six years if possible. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hereditary spherocytosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      An inherited deficiency of pyruvate kinase (PK) is the most common of the erythrocyte glycolytic enzyme deficiencies. The clinical spectrum ranges from a mild, completely compensated hemolytic state to severe anemia. Anemia and hyperbilirubinemia may occur in the neonatal period. In the older patient, pallor, scleral icterus, and splenomegaly are usual findings. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pyruvate kinase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common condition manifested by acute hemolytic episodes induced by infection or certain drugs (",
"      <a class=\"graphic graphic_table graphicRef74254 \" href=\"mobipreview.htm?19/22/19821\">",
"       table 2",
"      </a>",
"      ). Much less commonly, G6PD deficiency can cause a chronic hemolytic anemia. G6PD occurs in approximately 13 percent of black men and 2 percent of black women; a different genotype affects individuals of Mediterranean, Arabic, and Asian descent. Prevention of hemolysis by avoiding oxidant drugs is of paramount importance, so individuals in high risk groups should be tested for G6PD deficiency prior to administration of potent oxidant drugs. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Glucose-6-phosphate dehydrogenase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmune hemolytic anemia (AIHA) is characterized by autoantibodies to red blood cells. It may occur in an otherwise healthy individual (primary AIHA) or in the setting of an underlying systemic disorder such as an autoimmune disease, malignancy, or immunodeficiency (secondary AIHA) (",
"      <a class=\"graphic graphic_table graphicRef57399 \" href=\"mobipreview.htm?16/26/16811\">",
"       table 4",
"      </a>",
"      ). There are three types of primary AIHA, each with a different underlying mechanism and approach to treatment (",
"      <a class=\"graphic graphic_table graphicRef55710 \" href=\"mobipreview.htm?12/53/13148\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H2936114\">",
"       'Autoimmune hemolytic anemias'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most common form of primary AIHA is warm-reactive disease, which is characterized by extravascular hemolysis, mainly in the spleen, with resulting splenomegaly, jaundice, and anemia. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Warm-reactive hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A second type of primary AIHA is cold-agglutinin disease, characterized by intravascular hemolysis with resulting hemoglobinemia and hemoglobinuria. Dark-colored urine is more common and splenomegaly is less common than in warm-reactive disease. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Cold-agglutinin hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A third type of primary AIHA is paroxysmal cold hemoglobinuria, characterized by intravascular hemolysis with hemoglobinemia, hemoglobinuria, and anemia. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Paroxysmal cold hemoglobinuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal nocturnal hemoglobinuria (PNH) is a rare chronic anemia with prominent intravascular hemolysis that may have its onset in late childhood. Hemolysis is characteristically worse during sleep, with morning hemoglobinuria usually present. The diagnosis is established by a positive result in the acidified serum (Ham test), or thrombin or sucrose lysis tests. (See",
"      <a class=\"local\" href=\"#H2935927\">",
"       'Paroxysmal nocturnal hemoglobinuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Recht M, Pearson H. The hemolytic anemias. In: Oski's Pediatrics, McMillan JA, Deangelis CD, Feigin RD, Warshaw JB (Eds), Lippincott Williams and Wilkins, Philadelphia 1999. p.1453.",
"    </li>",
"    <li>",
"     Oski FA, Brugnara C, Nathan DG. A diagnostic approach to the anemic patient. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Philadelphia 2003. p.409.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/3\">",
"      Davis BH, Ornvold K, Bigelow NC. Flow cytometric reticulocyte maturity index: a useful laboratory parameter of erythropoietic activity in anemia. Cytometry 1995; 22:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/4\">",
"      Olivieri N. Thalassaemia: clinical management. Baillieres Clin Haematol 1998; 11:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/5\">",
"      Senaati S, Gumruk FU, Delbakhsh P, et al. Gallbladder pathology in pediatric beta-thalassemic patients. A prospective ultrasonographic study. Pediatr Radiol 1993; 23:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/6\">",
"      Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/7\">",
"      Gallagher PG, Forget BG. Hematologically important mutations: spectrin and ankyrin variants in hereditary spherocytosis. Blood Cells Mol Dis 1998; 24:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/8\">",
"      Chilcote RR, Le Beau MM, Dampier C, et al. Association of red cell spherocytosis with deletion of the short arm of chromosome 8. Blood 1987; 69:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/9\">",
"      Palek J. Hereditary elliptocytosis, spherocytosis and related disorders: consequences of a deficiency or a mutation of membrane skeletal proteins. Blood Rev 1987; 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/10\">",
"      Eber SW, Gonzalez JM, Lux ML, et al. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nat Genet 1996; 13:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/11\">",
"      Rescorla FJ. Laparoscopic splenectomy. Semin Pediatr Surg 1998; 7:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/12\">",
"      Goss GA, Szer J. Pancytopenia following infection with human parvovirus B19 as a presenting feature of hereditary spherocytosis in two siblings. Aust N Z J Med 1997; 27:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/13\">",
"      Fogel BJ, Shields CE, Altstatt LB, et al. Determining the. A method especially applicable to pediatrics. Clin Pediatr 1967; 6:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/14\">",
"      Judkiewicz L, Bartosz G, Oplatowska A, Szczepanek A. Modified osmotic fragility test for the laboratory diagnosis of hereditary spherocytosis. Am J Hematol 1989; 31:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/15\">",
"      Caprotti R, Porta G, Franciosi C, et al. Laparoscopic splenectomy for hematological disorders. Our experience in adult and pediatric patients. Int Surg 1998; 83:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/16\">",
"      Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122:187.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/18\">",
"      Buchanan GR. Chemoprophylaxis in asplenic adolescents and young adults. Pediatr Infect Dis J 1993; 12:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/19\">",
"      Silveira P, Cynober T, Dhermy D, et al. Red blood cell abnormalities in hereditary elliptocytosis and their relevance to variable clinical expression. Am J Clin Pathol 1997; 108:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/20\">",
"      Lux SE, Wolfe LC. Inherited disorders of the red cell membrane skeleton. Pediatr Clin North Am 1980; 27:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/21\">",
"      Palek J, Jarolim P. Clinical expression and laboratory detection of red blood cell membrane protein mutations. Semin Hematol 1993; 30:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/22\">",
"      Eyssette-Guerreau S, Bader-Meunier B, Garcon L, et al. Infantile pyknocytosis: a cause of haemolytic anaemia of the newborn. Br J Haematol 2006; 133:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/23\">",
"      Baronciani L, Bianchi P, Zanella A. Hematologically important mutations: red cell pyruvate kinase (2nd update). Blood Cells Mol Dis 1998; 24:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/24\">",
"      McMullin MF. The molecular basis of disorders of red cell enzymes. J Clin Pathol 1999; 52:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/25\">",
"      Necheles TF, Finkel HE, Sheehan RG, Allen DM. Red cell pyruvate kinase deficiency. The effect of splenectomy. Arch Intern Med 1966; 118:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/26\">",
"      BOYER SH, PORTER IH, WEILBACHER RG. Electrophoretic heterogeneity of glucose-6-phosphate dehydrogenase and its relationship to enzyme deficiency in man. Proc Natl Acad Sci U S A 1962; 48:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/27\">",
"      Oppenheim A, Jury CL, Rund D, et al. G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. Hum Genet 1993; 91:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/28\">",
"      Holl&aacute;n S, Fujii H, Hirono A, et al. Hereditary triosephosphate isomerase (TPI) deficiency: two severely affected brothers one with and one without neurological symptoms. Hum Genet 1993; 92:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/29\">",
"      Jacob HS. Mechanisms of Heinz body formation and attachment to red cell membrane. Semin Hematol 1970; 7:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/30\">",
"      Habibi B, Homberg JC, Schaison G, Salmon C. Autoimmune hemolytic anemia in children. A review of 80 cases. Am J Med 1974; 56:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/31\">",
"      Izui S. Autoimmune hemolytic anemia. Curr Opin Immunol 1994; 6:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/32\">",
"      Buchanan GR, Boxer LA, Nathan DG. The acute and transient nature of idiopathic immune hemolytic anemia in childhood. J Pediatr 1976; 88:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/33\">",
"      Burkart PT, Hsu TC. IgM cold-warm hemolysins in infectious mononucleosis. Transfusion 1979; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/34\">",
"      Wilkinson LS, Petz LD, Garratty G. Reappraisal of the role of anti-i in haemolytic anaemia in infectious mononucleosis. Br J Haematol 1973; 25:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/35\">",
"      Heddle NM. Acute paroxysmal cold hemoglobinuria. Transfus Med Rev 1989; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/36\">",
"      van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol 2005; 128:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/37\">",
"      Tomita M. Biochemical background of paroxysmal nocturnal hemoglobinuria. Biochim Biophys Acta 1999; 1455:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/38\">",
"      Kanai N, Vreeke TM, Parker CJ. Paroxysmal nocturnal hemoglobinuria: analysis of the effects of mutant PIG-A on gene expression. Am J Hematol 1999; 61:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/39\">",
"      Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood 1982; 60:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/40\">",
"      Bemba M, Guardiola P, Garderet L, et al. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999; 105:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/60/43977/abstract/41\">",
"      Flotho C, Strahm B, Kontny U, et al. Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood. Br J Haematol 2002; 118:124.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5932 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-4E1BBEB838-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43977=[""].join("\n");
var outline_f42_60_43977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2998504\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF THE HEMOLYTIC PROCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INTRINSIC HEMOLYTIC ANEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25094836\">",
"      Hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hereditary spherocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hereditary elliptocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hereditary stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Abnormalities of erythrocyte glycolytic enzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pyruvate kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Other glycolytic enzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other pentose phosphate pathway enzymes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      EXTRINSIC HEMOLYTIC ANEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2936114\">",
"      Autoimmune hemolytic anemias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Warm-reactive hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Cold-agglutinin hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2935927\">",
"      Paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2998504\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5932|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/9/31895\" title=\"picture 1\">",
"      Polychromatophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/61/36822\" title=\"picture 2\">",
"      Reticulocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/42/40611\" title=\"picture 3\">",
"      Normal marrow aspirate low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/36/43589\" title=\"picture 4\">",
"      Erythroid hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/1/27670\" title=\"picture 5\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/61/10199\" title=\"picture 6\">",
"      Elliptocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/51/9015\" title=\"picture 7\">",
"      Stomatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/28/26054\" title=\"picture 8\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/10/15527\" title=\"picture 9\">",
"      Cold agglutinin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/31/508\" title=\"table 1\">",
"      Causes of hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/22/19821\" title=\"table 2\">",
"      Drugs and G6PD deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/53/13148\" title=\"table 3\">",
"      Pathophysiology and therapy of AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/26/16811\" title=\"table 4\">",
"      Classification of AIHA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/56/43911?source=related_link\">",
"      Hereditary elliptocytosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40500?source=related_link\">",
"      Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42392?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13593?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28596?source=related_link\">",
"      Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44341?source=related_link\">",
"      Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27559?source=related_link\">",
"      Pyruvate kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/616?source=related_link\">",
"      Unstable hemoglobin variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14583?source=related_link\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_60_43978="Advanced case 10";
var content_f42_60_43978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1253px;\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Advanced case 10",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43978=[""].join("\n");
var outline_f42_60_43978=null;
var title_f42_60_43979="Criteria for severe preeclampsia";
var content_f42_60_43979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The presence of one or more of the following criteria upstages preeclampsia from mild to severe",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Symptoms of central nervous system dysfunction:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Visual disturbance (photopsia, scotomata, cortical blindness, retinal vasospasm)",
"        </p>",
"        <p>",
"         Severe headache (ie, incapacitating, \"the worst headache I've ever had\") or headache that persists and progresses despite analgesic therapy",
"        </p>",
"        <p>",
"         Altered mental status&nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Symptoms of liver capsule distention:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right upper quadrant or epigastric pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nausea, vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hepatocellular injury:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serum transaminase concentration &ge; twice normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Severe blood pressure elevation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systolic blood pressure &ge;160 mm Hg or diastolic blood pressure&nbsp;&ge;110 mm Hg on two occasions at least six hours apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thrombocytopenia:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &lt;100,000 platelets/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Proteinuria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;5 grams in 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oliguria &lt;500 mL in 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal growth restriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema or cyanosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from&nbsp;Diagnosis and Management of Preeclampsia and Eclampsia. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #33, January 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43979=[""].join("\n");
var outline_f42_60_43979=null;
var title_f42_60_43980="Effect of SO4 on H and K";
var content_f42_60_43980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of nonreabsorbable anion on potassium and hydrogen secretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 247px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Events occurring after Na reabsorption across the luminal membrane in the cortical collecting tubule. In the sodium-avid state, the presentation of Na with a nonreabsorbable anion such as SO4(2-) enhances H and K secretion. In contrast, if NaCl is presented to this segment, Na will be reabsorbed with Cl, with little effect on H and K secretion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43980=[""].join("\n");
var outline_f42_60_43980=null;
var title_f42_60_43981="PAH reversal in mitral stenosis";
var content_f42_60_43981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reversibility of pulmonary hypertension in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean pulmonary artery (PA) systolic pressure after correction of mitral stenosis with balloon valvuloplasty or surgical commisurotomy. Mean PA pressure fell progressively with both procedures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Reyes VP, Raju BS, Wynne J, et al. N Engl J Med 1994; 331:961.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43981=[""].join("\n");
var outline_f42_60_43981=null;
var title_f42_60_43982="Anions - Cations and the anion gap";
var content_f42_60_43982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Anions - Cations and the anion gap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43982=[""].join("\n");
var outline_f42_60_43982=null;
var title_f42_60_43983="Immediate release preparations";
var content_f42_60_43983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81815%7EPEDS%2F77580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81815%7EPEDS%2F77580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immediate-release stimulant preparations for children with attention deficit hyperactivity disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication (how supplied)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;US trade name (generic availability)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;Duration of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose advancement*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose (per day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Methylphenidate",
"        </p>",
"        <p>",
"         (5, 10, 20 mg tablets; 2.5, 5, 10 mg chewable tablets; 5 mg/5 mL flavored oral solution, 10 mg/5 mL flavored oral solution)",
"        </p>",
"       </td>",
"       <td class=\"indent1\">",
"        <p>",
"         Ritalin",
"         <sup>",
"          &reg;",
"         </sup>",
"         (generic available)",
"        </p>",
"        <p>",
"         Methylin",
"         <sup>",
"          &reg;",
"         </sup>",
"         chewable tablets (generic available)",
"        </p>",
"        <p>",
"         Methylin",
"         <sup>",
"          &reg;",
"         </sup>",
"         oral suspension (generic available)",
"        </p>",
"       </td>",
"       <td class=\"indent1\">",
"        3 to 5 hours&nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         5 mg/day x 1 day; then",
"        </p>",
"        <p>",
"         5 mg 2 times per day",
"        </p>",
"        <p>",
"         Children &le;25 kg may be started with 2.5 mg per day.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Increments of 5 mg per day every 3 to 7 days",
"        </p>",
"        <p>",
"         Children &le;25 kg may be increased by 2.5 mg per day every 3 to 7 days.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &le;25 kg: 35 mg",
"        </p>",
"        <p>",
"         25 kg: 60 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Dexmethylphenidate",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         (2.5, 5, 10 mg tablets, non-scored)",
"        </p>",
"       </td>",
"       <td class=\"indent1\">",
"        Focalin",
"        <sup>",
"         &reg;",
"        </sup>",
"        (generic available)",
"       </td>",
"       <td class=\"indent1\">",
"        5 to 6 hours",
"       </td>",
"       <td>",
"        2.5 mg 2 times per day (patients not taking methylphenidate). For patients taking methylphenidate dose is half current daily dose up to 10 mg twice per day.",
"       </td>",
"       <td>",
"        Increments of 2.5 to 5 mg&nbsp;per day every 3 to 7 days",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        <p>",
"         Dextroamphetamine",
"        </p>",
"        <p>",
"         (5, 10 mg scored tablets; 5 mg/5mL flavored oral solution)",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Dexedrine",
"        <sup>",
"         &reg;",
"        </sup>",
"        ,",
"        <p>",
"         DextroStat",
"         <sup>",
"          &reg;",
"         </sup>",
"         (generic available), ProCentra",
"         <sup>",
"          &reg;",
"         </sup>",
"         oral solution",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        4 to 6 hours",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        3 to 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         2.5 mg/day x 1 day",
"        </p>",
"        <p>",
"         2.5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 2.5 mg per day every 3 to 7 days",
"       </td>",
"       <td class=\"sublist_other\">",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        &ge;6 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         5 mg x 1 day",
"        </p>",
"        <p>",
"         5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 5 mg per day every 3 to 7 days",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         &le;50 kg: 40 mg",
"        </p>",
"        <p>",
"         &gt;50 kg: 60 mg",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        <p>",
"         Amphetamine-dextroamphetamine",
"        </p>",
"        <p>",
"         (5, 7.5, 10, 12.5, 15, 20, 30 mg scored tablets)",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        <p>",
"         Adderall",
"         <sup>",
"          &reg;",
"         </sup>",
"         (generic available)",
"        </p>",
"       </td>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        4 to 6 hours",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        3 to 5 years",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         &le;50 kg: 40 mg",
"        </p>",
"        <p>",
"         &gt;50 kg: 60 mg",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         2.5 mg/day x 1 day",
"        </p>",
"        <p>",
"         2.5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 2.5 mg per day every 3 to 7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        &ge;6 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         &ge;5 mg x 1 day",
"        </p>",
"        <p>",
"         5 mg 2 times/day",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Increments of 5 mg per day every 3 to 7 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Doses of immediate-release preparations are given in morning on rising and at lunch time 4 to 6 hours later. Three times per day dosing is an option for children needing control of symptoms in late afternoon or early evening.",
"     <br>",
"      &bull; Dexmethylphenidate may not be an appropriate choice for children aged &lt;6 years due to its relatively higher potency and lack of commercially available chewable tablets or flavored oral solution.",
"      <br>",
"       &Delta; Doses above 40 mg per day total are rarely needed and warrant close monitoring for adverse effects.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      References:",
"     </p>",
"     <ol>",
"      <li>",
"       Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"      </li>",
"      <li>",
"       Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Supplemental information. Pediatrics 2011.",
"      </li>",
"      <li>",
"       Drugs for treatment of ADHD. Treat Guidel Med Lett 2011; 9:24.",
"      </li>",
"      <li>",
"       Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intermediate- and long-acting medications for children with attention deficit hyperactivity disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name",
"        <br/>",
"        (generic availability)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description of release and duration of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose advancement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose",
"        <br/>",
"        (per day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Methylphenidate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate-SR",
"        <br/>",
"        (20 mg tablets)",
"       </td>",
"       <td>",
"        Ritalin-SR (generic available)",
"       </td>",
"       <td>",
"        Delayed onset with continuous release over 3 to 8 hours. May require twice daily dosing and/or use with immediate-release methylphenidate.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 20 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate ER",
"        <br/>",
"        (10, 20 mg tablets)",
"       </td>",
"       <td>",
"        Metadate ER (generic available)",
"       </td>",
"       <td>",
"        Delayed onset with continuous release over 3 to 8 hours. May require twice daily dosing and/or use with immediate-release methylphenidate.",
"       </td>",
"       <td>",
"        10 mg",
"       </td>",
"       <td>",
"        Increments of 10 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate LA",
"        <br/>",
"        (10, 20, 30, 40 mg capsules)",
"       </td>",
"       <td>",
"        Ritalin LA (generic available except 10 mg)",
"       </td>",
"       <td>",
"        <p>",
"         50 percent immediate-release and 50 percent delayed-release over 8 to 12 hours (bi-modal).",
"        </p>",
"        Capsule may be opened and contents sprinkled over spoonful of cold applesauce or other thick substance (eg, peanut butter); capsule should not be crushed or chewed.",
"       </td>",
"       <td>",
"        10 or 20 mg",
"       </td>",
"       <td>",
"        Increments of 10 or 20 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate CD",
"        <br/>",
"        (10, 20, 30, 40, 50, 60 mg capsules)",
"       </td>",
"       <td>",
"        Metadate CD",
"       </td>",
"       <td>",
"        <p>",
"         30 percent immediate-release and 70 percent delayed-release over 8 to 12 hours (bi-modal).",
"        </p>",
"        Capsule may be opened and contents sprinkled over spoonful of cold applesauce or other thick substance (eg, peanut butter); capsule should not be crushed or chewed.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 10 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate ER",
"        <br/>",
"        (18, 27, 36, 54 mg tablets)",
"       </td>",
"       <td>",
"        Concerta (generic available)",
"       </td>",
"       <td>",
"        <p>",
"         20 percent immediate-release and 80 percent continuous-release over 10 to 12 hours by osmotic delivery.",
"        </p>",
"        Tablet must be swallowed whole.",
"       </td>",
"       <td>",
"        18 mg",
"       </td>",
"       <td>",
"        Increments of 9 to 18 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &lt;13 years: 54 mg",
"        </p>",
"        &ge;13 years: 72 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate XR oral suspension",
"        <br/>",
"        (5 mg/mL)",
"       </td>",
"       <td>",
"        Quillivant XR",
"       </td>",
"       <td>",
"        20 percent immediate-release and 80 percent extended-release for duration of action up to 12 hours.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 10 mg every 7 days",
"       </td>",
"       <td>",
"        60 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate patch",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <br/>",
"        (10, 15, 20, 30 mg patch)",
"       </td>",
"       <td>",
"        Daytrana",
"       </td>",
"       <td>",
"        Onset 2 hours after application of patch and continuous release over 10 to 12 hours.",
"       </td>",
"       <td>",
"        10 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increments of 5 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        30 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Dexmethylphenidate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexmethylphenidate XR",
"        <br/>",
"        (5, 10, 15, 20, 25, 30, 35, 40 mg capsules)",
"       </td>",
"       <td>",
"        Focalin XR",
"       </td>",
"       <td>",
"        <p>",
"         Fifty percent immediate-release and 50 percent delayed release over 10 to 12 hours (bi-modal).",
"        </p>",
"        Capsule may be opened and contents sprinkled over spoonful of cold applesauce or other thick substance (eg, peanut butter); capsule should not be crushed or chewed.",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        Increments of 5 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Amphetamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dextroamphetamine SR",
"        <br/>",
"        (5, 10, 15 mg capsules)",
"       </td>",
"       <td>",
"        Dexedrine spansule (generic extended-release available)",
"       </td>",
"       <td>",
"        Combination of immediate- and continuous-release over 6 to 8 hours. May require dividing dose twice daily.",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        Increments of 5 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 40 mg",
"        </p>",
"        &gt;50 kg: 60 mg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amphetamine-dextroamphetamine ER",
"        <br/>",
"        (5, 10, 15, 20, 25, 30 mg capsules)",
"       </td>",
"       <td>",
"        Adderall XR (generic available)",
"       </td>",
"       <td>",
"        Combination of immediate- and continuous-release over 8 to 10 hours.",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        Increments of 5 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lisdexamfetamine",
"        <br/>",
"        (20, 30, 40, 50, 60, 70 mg capsules)",
"       </td>",
"       <td>",
"        Vyvanse",
"       </td>",
"       <td>",
"        <p>",
"         Prodrug converted to dextroamphetamine in bloodstream with an effect over ~10 hours.",
"        </p>",
"        Capsule may be opened and dissolved in water for immediate use.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 10 or 20 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        70 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Non-stimulants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"6\">",
"        Selective norepinephrine reuptake inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Atomoxetine",
"        <br/>",
"        (10, 18, 25, 40, 60, 80, 100 mg capsules)",
"       </td>",
"       <td>",
"        Strattera",
"       </td>",
"       <td>",
"        At least 10 to 12 hours",
"       </td>",
"       <td>",
"        0.5 mg/kg per day for minimum of 3 days",
"       </td>",
"       <td>",
"        Increase to 1.2 mg/kg per day after a minimum of 3 days (maximum 100 mg per day)",
"       </td>",
"       <td>",
"        Lesser or 1.4 mg/kg or 100 mg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"6\">",
"        Alpha-2 adrenergic agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Extended release guanfacine",
"        <sup>",
"         &sect;",
"        </sup>",
"        <br/>",
"        (1, 2, 3, 4 mg tablets)",
"       </td>",
"       <td>",
"        Intuniv",
"       </td>",
"       <td>",
"        At least 10 to 12 hours",
"       </td>",
"       <td>",
"        1 mg per day",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Increments of 1 mg per day at no less than weekly intervals",
"       </td>",
"       <td>",
"        4 mg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Extended release clonidine",
"        <sup>",
"         &sect;",
"        </sup>",
"        <br/>",
"        (0.1 and 0.2 mg tablets)",
"       </td>",
"       <td>",
"        Kapvay",
"       </td>",
"       <td>",
"        At least 10 to 12 hours",
"       </td>",
"       <td>",
"        0.1 mg at bedtime on days 1 through 7",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Increments of 0.1 mg per day at no less than weekly intervals. For titration, divide dose twice daily, either equally or higher dose at bedtime.",
"       </td>",
"       <td>",
"        0.4 mg per day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SR: sustained release; LA: long-acting; ER: extended release; CD: controlled dispense; XR: extended release.",
"     <br/>",
"     * Suggested doses for initiating treatment with long-acting stimulant medications for treatment of children aged &ge;6 years.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     This maximum dose exceeds the US Food and Drug Administration-approved maximum dose; careful monitoring for adverse effects is warranted.",
"     <br/>",
"     &Delta; Patch is applied 2 hours before needed effect and worn for a total of 9 hours. Doses for the methylphenidate patch are not equivalent to those for the oral preparations.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Doses above 40 mg per day total are rarely necessary and warrant close monitoring.",
"     <br/>",
"     &sect; Immediate-release form cannot be substituted mg for mg for extended-release due to pharmacokinetic differences. Discontinuation requires dose tapering to prevent rebound increase in blood pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"      </li>",
"      <li>",
"       Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Supplemental information. Pediatrics 2011.",
"      </li>",
"      <li>",
"       Drugs for treatment of ADHD. Treat Guidel Med Lett 2011; 9:23.",
"      </li>",
"      <li>",
"       Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.",
"      </li>",
"      <li>",
"       Quillivant XR prescribing information. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2012/202100lbl.pdf (Accessed on November 15, 2012).",
"      </li>",
"      <li>",
"       Quillivant XR - An extended-release oral suspension of methylphenidate. The Medical Letter 2013; 55:10.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_60_43983=[""].join("\n");
var outline_f42_60_43983=null;
